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ABSTRACT 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease 
is a fatal neurodegenerative disease. ALS is typically adult onset and is 
characterized by rapidly progressive loss of both upper and lower motor neurons 
that leads to death usually within 3-5 years. About 90% of all the cases are 
sporadic with no family history while the remaining 10% are familial cases with 
mutations in several genes including SOD1, FUS/TLS, TDP43 and C9ORF72. 
FUS/TLS (Fused in Sarcoma/Translocated in Liposarcoma or FUS) is an 
RNA/DNA binding protein that is involved in multiple cellular functions including 
DNA damage repair, transcription, mRNA splicing, RNA transport and stress 
response. More than 40 mutations have now been identified in FUS that account 
for about 5% of all the familial cases of ALS. However, the exact mechanism by 
which FUS causes ALS is unknown.  While significant progress has been made 
in understanding the disease mechanism and identifying therapeutic strategies, 
several questions still remain largely unknown. The work presented here aims at 
understanding the normal functions of FUS as well as the pathogenic 
mechanisms by which it leads to disease.  
Several studies showed the association of mutant-FUS with structures 
made up of RNA and proteins, called stress granules that form under various 
stress conditions. However, little is known about the role of endogenous FUS 
under stress conditions. I have shown that under hyperosmolar conditions, the 
predominantly nuclear FUS translocates into the cytoplasm and incorporates into 
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stress granules. The response is specific to hyperosmolar stress because FUS 
remains nuclear under other stress conditions tested, such as oxidative stress, 
ER stress and heat shock. The response of FUS is rapid, and cells with reduced 
FUS levels are susceptible to the hyperosmolar stress, indicating a pro-survival 
role for FUS. In addition to investigating the functions of endogenous wild-type 
(WT) FUS, the work presented also focuses on identifying the pathogenic 
mechanism(s) of FUS variants. Using various biochemical techniques, I have 
shown that ALS-causing FUS variants are misfolded compared to the WT 
protein.  Furthermore, in a squid axoplasm based vesicle motility assay, the FUS 
variants inhibit fast axonal transport (FAT) in a p38 MAPK dependent manner, 
indicating a role for the kinase in mutant-FUS mediated disease pathogenesis. 
Analysis of human ALS patient samples indicates higher levels of total and 
phospho p38, supporting the notion that aberrant regulation of p38 MAPK is 
involved in ALS. 
The results presented in this dissertation 1) support a novel prosurvival 
role for FUS under hyperosmolar stress conditions and, 2) demonstrate that 
protein misfolding and aberrant kinase activation contribute to ALS pathogenesis 
by FUS variants.   
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CHAPTER I 
INTRODUCTION 
AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, 
is a fatal neurodegenerative disease that primarily affects the upper and lower 
motor neurons of the brain and spinal cord. Typically an adult onset disease, ALS 
progresses very rapidly and leads to the death usually within 3-5 years after 
onset. Even though the disease has been known for over 100 years, there is not 
a complete understanding of this complex disease nor is there an effective 
treatment or cure.  
SIGNS AND SYMPTOMS 
Diseases affecting the motor neurons are often referred to as motor 
neuron diseases (MNDs) and include diseases such as ALS, progressive bulbar 
palsy, pseudobulbar palsy, primary lateral sclerosis, spinal muscular atrophy and 
post-polio syndrome (NINDS, 2013). ALS affects both upper and lower motor 
neurons while most other MNDs are restricted to either upper or lower motor 
neurons (NINDS, 2013). Even though descriptions of ALS-like symptoms were 
reported early in the 19th century (Rowland, 2001), Jean-Martin Charcot, also 
known as the father of modern neurology, is often credited for first identifying and 
using the term “amyotrophic lateral sclerosis” to describe the disease in 1874 
(Goetz, 2000; Rowland, 2001). Correlating autopsy pathology with clinical 
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symptoms, Charcot provided evidence for the degeneration of both upper motor 
neurons (UMN) and lower motor neurons (LMN) (Goetz, 2000; Rowland, 2001). 
The clinical symptoms of UMN degeneration include spasticity (muscle stiffness) 
and hyperreflexia (exaggerated reflexes) while that of LMN degeneration 
includes fasciculation (muscle twitching), cramps, muscle atrophy and weakness  
(Gordon, 2013; NINDS, 2013). Symptoms are first presented in only one 
particular group of muscles. For limb-onset ALS this would be either the arms or 
legs and for bulbar-onset ALS, muscles that control speech and swallowing. 
About two-thirds of the patients present limb-onset ALS, that often starts in one 
of the limbs, and then progresses very rapidly to other limbs and the rest of the 
body (Gordon, 2013). Some of the early symptoms include loss of dexterity, 
weakness and difficulty using the arms or legs. As the disease progresses, the 
patients lose the ability to move arms or walk (Gordon, 2013). On the other hand, 
in bulbar-onset ALS, which is observed in 20-30% of the patients, dysphagia 
(difficulty with swallowing) and dysarthria (difficulty with speech) are the most 
common symptoms (Gordon, 2013). Bulbar-onset ALS appears to have a worse 
prognosis, including shorter survival period, compared to limb-onset form of the 
disease (Chio et al., 2002; Magnus et al., 2002; del Aguila et al., 2003). 
Irrespective of the site of onset of the disease, during late stages of the disease, 
a combination of both UMN and LMN degeneration symptoms appear that 
ultimately culminates in death of the patient mostly likely due to respiratory and 
other cardio-pulmonary complications (Silani et al., 2011). 
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DIAGNOSIS AND TREATMENT 
The absence of a single confirmatory clinical test or reliable biomarker 
makes it challenging to diagnose ALS. The current diagnosis procedure relies on 
confirming LMN and UMN manifestations as well as excluding ALS-like diseases. 
Thus the current diagnosis involves not only a careful examination of the patient 
for motor neuron symptoms, but also includes a long list of tests to eliminate the 
ALS-mimicking diseases (Silani et al., 2011).  The “El Escorial criteria” (Brooks, 
1994; Brooks et al., 2000), developed by the World Federation of Neurology, 
have been formulated to assist in the diagnosis process and for research 
study/trial classification of ALS patients. The criterion depends on the number of 
regions (bulbar, cervical, thoracic, lumbosacral) affected and classifies patients 
into categories that include “clinically probable” to “clinically definite”. Despite the 
criteria and clinical advancements, the diagnosis often takes a long time, in some 
cases up to a year (Silani et al., 2011). Unfortunately, even after a definitive 
diagnosis there is no cure for this disease. Much of the attention is thus placed 
on managing the disease and prolonging life while trying to mitigate the 
symptoms as much as possible. Patients are often treated with Riluzole, the only 
treatment approved by US Food and Drug Administration (FDA) for ALS despite 
only being able to increase lifespan marginally – on the order of a few months 
(Zoccolella et al., 2007; Miller et al., 2012).  
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EPIDEMIOLOGY 
About 5,000 people are diagnosed with ALS each year in the US and 
there are about 20,000-30,000 people currently living with ALS in the US 
(NINDS, 2013). ALS is the most common neuromuscular disease and affects 
people throughout the world. Several studies have aimed at identifying the risk 
factors for ALS; however, most of these had weak findings and were often 
inconclusive and contradictory. Some of the major risk factors that have been 
investigated over the years are highlighted below: 
Gender – Several earlier studies reported nearly two-fold higher incidence rates 
in males compared to females although recent studies point toward indifference 
in gender based incidence rates (Logroscino et al., 2008). 
Ethnicity/race – Caucasian populations have been associated with higher 
incidence rates than Asian populations (Cronin et al., 2007). In the US, the 
incidence rates are lower in African-American and Hispanic populations than 
non-Hispanic Caucasians (Cronin et al., 2007).  
Geographical location and diet – ALS-like symptoms have been reported at a 
higher incidence rate among the Chamorro people of Guam and other Mariana 
islands (Papapetropoulos, 2007; Karamyan and Speth, 2008). The high 
incidence was later attributed, albeit without conclusive evidence, to β-
methylamino-L-alanine (BMAA) which was present in cycad seeds that are part 
of the dietary intake in those regions (Papapetropoulos, 2007; Karamyan and 
Speth, 2008). Dietary products in general have not been found as strong risk 
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factors for developing ALS. Other than BMAA, one study showed an inverse 
relation with chicken consumption; higher chicken consumption is associated 
with lower risk of ALS (Morozova et al., 2008).  
Alcohol consumption and smoking – While alcohol consumption is associated 
with lower risk of ALS (de Jong et al., 2012), cigarette smoking is often 
associated with higher risk of developing ALS (Wang et al., 2011; de Jong et al., 
2012). 
Physical activity and sports – It has been suspected that people involved in high 
intensity physical activities, such as sports, are at higher risk for developing ALS; 
however, the findings from several studies have been inconsistent and need 
further validation (Veldink et al., 2005; Chio et al., 2009; Beghi et al., 2010). One 
study found a significant increase in risk of ALS in Italian professional football 
players, although the increased risk has been attributed to not only football 
related activities, such as heading the ball (Piazza et al., 2004), but also to the 
use of performance enhancing drugs (Belli and Vanacore, 2005) and exposure to 
pesticides on the field (Chio et al., 2005).  
Exposure to toxins – Exposure to toxic chemicals during activities that might be 
related to agriculture, sports and/or war, has been suspected to increase the risk 
of ALS (Trojsi et al., 2013). 
Gulf war veterans – US veterans who served during Gulf war of 1991 had nearly 
twofold higher risk of ALS (Horner et al., 2003; Coffman et al., 2005). The exact 
reason for this increased risk is unclear, but exposure to cyanobacteria, BMAA or 
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other toxins has been suggested as a possible reason (Spencer et al., 1998; Cox 
et al., 2009). However, even non-deployed soldiers had similar rates of ALS 
incidence (Kasarskis et al., 2009)and the higher risk remained only during the 
decade following the war (Horner et al., 2008). 
FAMILIAL ALS 
About 10% of all the ALS cases have a family history of the disease and 
are categorized as familial ALS (fALS). The first ALS-causing mutations were 
identified in the gene Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 1993) 
and over 150 ALS-causing mutations have now been identified in SOD1. These 
mutations account for ~20% of the fALS cases.  Mutations in several other genes 
including FUS/TLS (Kwiatkowski et al., 2009; Vance et al., 2009), TARDP or 
TDP43 (Gitcho et al., 2008; Kabashi et al., 2008; Rutherford et al., 2008; 
Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008) and 
PFN1 (Wu et al., 2012), have also been linked to fALS and are all typically 
inherited in an autosomal dominant fashion (Gordon, 2013). More recently 
hexanucleotide repeat expansions of GGGGCC in C9ORF72 have also been 
linked to fALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011). All of these 
mutations combined, account for about 40-60% of all fALS cases. Thus, there is 
a huge interest in identifying the remaining ALS-causing genes. Much of the 
understanding about ALS has come from the studies of the genes involved in 
fALS. Histopathology studies show that the protein products of these genes are 
found in inclusions within the motor neurons and other cell types such as glia 
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(Gordon, 2013). In the case of C9ORF72, RNA foci containing the 
hexanucleotide repeat mRNA as well as inclusions that are positive for several 
proteins including TDP43 have been identified (Gendron et al., 2014). Studies on 
these genes showed that several cellular pathways are perturbed. Protein 
misfolding/aggregation, oxidative stress, altered calcium metabolism, 
mitochondrial dysfunction, defective axonal transport, excitotoxicity, altered RNA 
processing and inflammation have all been implicated in various stages of 
disease etiology (Pasinelli and Brown, 2006; Gordon, 2013).  
SPORADIC ALS 
About 90% of all ALS cases have no evidence of family history and are 
thus categorized as sporadic ALS (sALS). Despite the majority of all ALS cases 
being sporadic, much less is known about this form of the disease. The clinical 
symptoms of both sporadic and familial forms of ALS are largely 
indistinguishable, indicative of converging pathways between these two forms of 
the disease. Supporting this notion, mutations in many fALS-associated genes, 
such as SOD1, FUS and TDP43, have been found in sALS patients (Renton et 
al., 2014). The most common genetic cause of sALS is hexanucleotide repeat 
expansions in C9ORF72 gene, with about 7% of all sporadic cases involving 
repeat expansions (Renton et al., 2014). Despite all of these findings, only ~11% 
of all the sALS cases are accounted for by means of genetic mutations. 
Interestingly, pathological inclusions in several of the sALS patients contain the 
fALS-linked protein TDP43 and in few cases SOD1 and FUS, despite the 
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absence of any genetic mutations in them (Neumann et al., 2006; Deng et al., 
2010; Rotunno and Bosco, 2013). While protein misfolding has been implicated 
as the major reason for such association in inclusions, the precise mechanism or 
causal events are unclear.  
SIMILARITY TO FTLD 
Frontotemporal lobar degeneration (FTLD or FTD) is a group of 
pathologically and genetically heterogeneous neurodegenerative disorders that 
result in progressive damage to frontal and temporal lobes of the brain. 
Progressive loss of speech and behavior represent the hallmark characteristics 
of FTLD. About 50% of all cases are familial with mutations in genes such as 
MAPT (Hutton et al., 1998) and PGRN (Baker et al., 2006; Cruts et al., 2006). 
Although distinct from ALS, there is a strong overlap in diagnosis, pathology, and 
genetics of these two diseases that can affect the same family or even the same 
individual (Zago et al., 2011).  In fact, histological subtype classification of FTLD 
includes FTLD-TDP43 and FTLD-FUS, which are characterized by the inclusions 
positive for the respective proteins. While recent studies point toward a genetic 
link between ALS and FTLD by means of proteinaceous inclusions and mutations 
in genes such as TDP43 (Lagier-Tourenne et al., 2010; Mackenzie et al., 2010), 
the repeat expansions of C9ORF72 represent the strongest genetic link between 
these two diseases (Hardy and Rogaeva, 2013). Thus, despite the same proteins 
being involved with both diseases, it is still unclear as to what exact factors 
dictate the occurrence of one disease versus the other. 
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FUS/TLS and the FET FAMILY 
Mutations in FUS account for ~5% of the fALS cases. FUS belongs to the 
FET (previously TET) family of proteins that also includes EWS (Ewing 
Sarcoma), TAF15 (TATA box binding protein associated factor 68 kDa or 
TAFII68) and the Drosophila homolog SARFH (Law et al., 2006; Tan and 
Manley, 2009). The proteins of this family contain several conserved domains 
including the N-terminal QGSY-rich region, a Glycine-rich region, an RNA-
recognition motif (RRM), a zinc-binding domain and C-terminal RGG-rich 
domains (domain structure of FUS is shown in Fig. 1.1). The N-terminal 
transcriptional activation domain of FUS, EWS and TAF15 is found to be fused 
with the C-terminal DNA binding domains of many transcription factors in several 
sarcomas. The FET family proteins are ubiquitously expressed. They are 
predominantly localized in the nucleus; however, they shuttle between the 
nucleus and cytoplasm. They can bind DNA and RNA, and they are implicated in 
numerous cellular processes including transcription, RNA transport, splicing and 
translation. While these proteins all have similar functions, they also have several 
non-redundant functions that make each of them an interesting candidate to 
study. The general functions of FET family proteins and their role in cancer have 
been discussed in detail by several groups (Law et al., 2006; Riggi et al., 2007; 
Kovar, 2011) 
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Figure 1.1 Domain structure of FUS  
Depiction of FUS protein showing the various domains with residue numbers 
indicated below. QGSY-rich, glutamine-glycine-serine-tyrosine-rich; G-rich, 
glycine-rich; RRM, RNA recognition motif; RGG, arginine-glycine-glycine-rich; 
ZFD, zinc-finger domain; NLS, nuclear localization signal. 
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FUS IN CANCER 
A member of the FET family and an RNA/DNA binding protein, FUS was 
initially identified as part of a chimeric oncogene, resulting from a chromosomal 
translocation in myxoid liposarcomas (MLS). Multiple fusion-oncogenes like FUS-
CHOP (Crozat et al., 1993; Rabbitts et al., 1993), FUS-DDIT3, FUS-ERG 
(Ichikawa et al., 1994; Panagopoulos et al., 1994; Shing et al., 2003), FUS-ATF-1 
(Panagopoulos et al., 1994) and FUS-BBF2H7 (Storlazzi et al., 2003) have been 
identified in MLS and other cancers. The N-terminal transcriptional activation 
domain of FUS is fused with the DNA binding domain of the transcription factor 
and results in an abnormal transcription factor. A majority of the myxoid 
liposarcomas contain these fusions (Law et al., 2006) and transgenic mouse 
models of FUS-CHOP have shown that the presence of this fusion is sufficient to 
initiate cancer (Perez-Losada et al., 2000b; Perez-Losada et al., 2000a). 
Interestingly a recent study showed that FUS is a putative tumor suppressor and 
the levels of FUS regulate the tumor properties in prostate cancer models 
(Brooke et al., 2010).  Much of the earlier research on FUS was thus focused on 
understanding its role in these cancers. Nevertheless, the research helped 
identify several key cellular functions of FUS. 
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NORMAL FUS FUNCTIONS 
FUS normally functions across several tiers of the central dogma of 
biology, which represents the transfer of genetic information from DNA, to RNA, 
to proteins. Proteins in turn regulate the flow of this genetic information at various 
levels. A few of those proteins act at multiple levels of regulation. FUS is one 
such multifunctional protein and has been associated with several key cellular 
functions such as DNA damage repair, RNA processing and stress response.  
FUS interacts with both single- and double-stranded DNA (Baechtold et 
al., 1999). FUS is also known as hPOMp75 and is involved in homologous DNA-
pairing. It also associates with higher order DNA structures such as D-loops 
(Akhmedov et al., 1995; Baechtold et al., 1999; Bertrand et al., 1999) and G-
quadruplexes (Takahama and Oyoshi, 2013; Takahama et al., 2013). FUS is 
located at the telomeres (Dejardin and Kingston, 2009; Takahama et al., 2009) 
and the association of FUS with telomeres has been proposed to regulate 
telomere length (Takahama et al., 2013). FUS also rapidly localizes to sites of 
laser induced DNA damage indicating a role in DNA damage repair (Mastrocola 
et al., 2013; Rulten et al., 2013; Wang et al., 2013). FUS is known to act as 
transcriptional factor and regulate the expression of several genes including 
PGC-1α (Sanchez-Ramos et al., 2011) and CCND1 (Wang et al., 2008). 
FUS is also known as hnRNP (heterogeneous ribonuclear protein) P2, 
implying its role as an RNA binding protein (Calvio et al., 1995).  Early SELEX 
(systematic evolution of ligands by exponential enrichment) and EMSA 
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(electrophoretic mobility shift assays) analyses demonstrated that recombinant 
FUS selectively binds RNAs containing a GGUG motif with nanomolar affinity in 
vitro (Lerga et al., 2001).  However, recent RNA cross-linking and deep-
sequencing studies aimed at identifying mRNAs bound by FUS in vivo have 
generated mixed results ((Hoell et al., 2011; Colombrita et al., 2012; Ishigaki et 
al., 2012; Lagier-Tourenne et al., 2012; Rogelj et al., 2012; Nakaya et al., 2013) 
and table 1.1). Thus, even though FUS is able to bind GU-rich sequences in vitro 
and in vivo, it appears that such sequences are neither sufficient nor required for 
interactions between FUS and RNA. A consistent finding across most RNA 
cross-linking and deep-sequencing studies is the binding of FUS to long introns.  
One functional outcome of the binding of FUS to RNA transcripts is the 
regulation of mRNA splicing. A role for FUS in splicing was suggested from 
earlier observations that FUS associated with components of the spliceosome 
(Yang et al. 1998; Meissner et al. 2003; Kameoka et al. 2004) and regulated 5’-
splice site selection in E1A pre-mRNA (Lerga, JBC, 2001; Hallier, JBC 1998).  
The global effect of FUS on alternative splicing has been recently revealed 
through several genome-wide exon array analyses (reviewed in (Ling et al., 
2013) and table 1.1). These studies demonstrated that FUS binds several 
hundreds of mRNAs including its own mRNA, suggesting an autoregulatory 
mechanism for FUS expression (Lagier-Tourenne et al., 2012; Nakaya et al., 
2013). Zhou et al recently demonstrated that FUS regulates splicing of exon 7, 
but that this splicing activity is impaired for FUS variants that mislocalize to the 
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cytoplasm (Zhou et al., 2013).  A misregulation of FUS expression may in turn 
contribute to the pathogenic accumulation of FUS that is observed in disease.   
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  Investigations of FUS in RNA processes 
Publication: 
General description 
mRNA 
Expression 
(method) 
mRNA 
Splicing 
(method) 
Binding 
targets 
(method) 
RNA 
binding 
specificity 
Key categories identified by 
Gene Ontology (GO) Term 
analysis 
Hoell et 
al., 2011 
Comparison of 
FET family and 
mutant FUS 
RNA targets 
FUS 
knockdown in 
HEK-293 cells  
(microarray) 
N/A 
HA-tagged 
WT, R521H 
or R521G in 
HEK-293 
cells  
(PAR-CLIPi) 
Introns; AU-
rich stem 
loops (15-
fold higher 
affinity than 
GGU 
repeat) 
RNAs uniquely bound by mutant-
FUS: endoplasmic reticulum and 
ubiquitin-proteasome related  
 
Colombrita 
et al., 
2012 
Comparison of 
FUS and TDP-
43 RNA targets 
N/A N/A 
Cytoplasmic 
fraction of 
NSC-34 
(RIP-CHIPii) 
3'UTR; 
limited 
sequence 
specificity 
RNAs bound by FUS: 
transcriptional regulation, cell 
cycle, ribonucleoprotein 
biogenesis, RNA splicing, stress 
response/ DNA repair, purine 
ribonucleotide binding and 
ubiquitin-mediated proteolysis 
Ishigaki et 
al., 2012 
RNA binding 
specificity of 
FUS; 
expression and 
splicing 
regulation by 
FUS 
FUS 
knockdown in 
primary cortical 
neurons  
(exon array) 
FUS 
knockdown in 
primary cortical 
neurons  
(exon array) 
mouse 
cerebellum  
(HITS-
CLIPiii) 
Introns and 
3'UTR; 
regions with 
secondary 
structure 
Changes in mRNA abundance: 
signaling cascades and metabolic 
processes 
Alternatively spliced mRNA: 
vesicle transport, neuronal 
impulse and neuronal projection 
Rogelj et 
al., 2012 
Comparison of 
FUS and TDP-
43 RNA 
targets; 
expression and 
splicing 
regulation by 
FUS 
FUS -/- 
embryonic 
mouse brain  
(splice-junction 
microarray) 
FUS -/- 
embryonic 
mouse brain  
(splice-junction 
microarray) 
embryonic 
mouse 
brain  
(iCLIPiv) 
Long 
introns; no 
preference 
for stem-
loops; 
limited 
sequence 
specificity 
Alternatively spliced mRNA: cell 
adhesion, apoptosis, neuronal 
development and axonogenesis 
Lagier-
Tourenne 
et al., 
2012 
Species 
comparison of 
FUS RNA 
targets; 
comparison of 
targets, 
expression and 
splicing 
regulation 
between FUS 
and TDP-43 
FUS 
knockdown in 
adult mouse 
brain and 
spinal cord 
(RNA-seq) 
FUS -/- 
embryonic 
mouse brain; 
FUS 
knockdown in 
adult mouse 
brain  
(splicing-
sensitive 
microarrays) 
Naïve 
mouse 
brain; non-
disease 
human 
brain  
(CLIP-seqv) 
Long introns 
and 3'UTR; 
GUGGU is 
an enriched 
RNA 
sequence 
motif 
RNAs bound by FUS: components 
of the synapse and molecules 
residing in neuronal projections 
Nakaya et 
al., 2013 
Species 
comparison of 
FUS RNA 
targets; 
expression and 
splicing 
regulation by 
FUS 
FUS 
knockdown in 
embryonic 
stem cell 
(ESC) derived 
mouse 
neurons  
(RNA-seq) 
FUS 
knockdown in 
ESC derived 
mouse 
neurons  
(RNA-seq) 
human 
temporal 
lobe 
cortices; 
ESC 
derived 
mouse 
neurons  
(HITS-
CLIPiii) 
Introns; 
limited 
sequence 
specificity 
RNAs bound by FUS: synapse, 
cell adhesion, neuronal projection 
and neuronal recogni ion 
processes 
van 
Blitterswijk 
et al., 
2013 
Comparison of 
FUS 
overexpression, 
FUS 
knockdown and 
expression of 
mutant-FUS on 
mRNA 
expression and 
splicing 
FUS 
knockdown; 
overexpression 
of WT, R521G 
or R522G in 
HEK-293 cells  
(RNA-seq) 
FUS 
knockdown; 
overexpression 
of WT, R521G 
or R522G in 
HEK-293 cells  
(RNA-seq) 
N/A N/A 
Changes in mRNA abundance: 
ribosome, spliceosome, mismatch 
repair and DNA replication 
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Table 1.1 Summary of investigations of FUS involvement in RNA 
processes. 
iPAR-CLIP – photoactivatable ribonucleoside-enhanced crosslinking and 
immunoprecipitation 
iiRIP-Chip - RNA-binding protein immunopurification, microarray 
iiiHITS-CLIP - High-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation 
iviCLIP – individual-nucleotide resolution crosslinking and immunoprecipitation 
vCLIP-seq – crosslinking immunoprecipitation, high-throughput sequencing 
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Another functional outcome of FUS binding to RNA is the transport of RNA 
from the nucleus to the cytoplasm and throughout the cell. While FUS is 
predominantly expressed in the nucleus of most cells, it shuttles between the 
nucleus and cytoplasm (Zinszner et al., 1997). Using heterocells formed by 
fusion of human and mouse or Xenopus cells, Zinszner et al. demonstrated 
nucleo-cytoplasmic shuttling of FUS was functionally linked to the transport of 
mRNA from the nucleus to the cytoplasm (Zinszner et al., 1997).  The nuclear 
localization of FUS is mediated by the nuclear import receptor transportin (or 
karyopherinβ2) (Dormann et al., 2010), an interaction that is modulated by 
methylation of arginine residues within FUS (Dormann et al., 2012).  Arginine-
methylation, catalyzed by protein arginine methyltransferases (PRMT), 
represents a post-translational modification that regulates the subcellular 
localization and function of proteins (Bedford and Clarke, 2009).  
FUS has been identified to associate with several motor proteins, 
including the ATP-dependent actin binding motors Myo5A (Yoshimura et al. 
2006) and Myo6 (Takarada et al. 2009), and it has also been isolated as part of 
the large granule that associates with the microtubule-dependent kinesin motor 
protein KIF5B (Kanai et al., 2004).  The association of FUS with such transport 
machinery and the transport of FUS to different regions of the cell may be 
important for FUS mediated local translation (Fujii et al., 2005; Fujii and Takumi, 
2005; Yasuda et al., 2013).  In response to the glutamate receptor mGluR5 
mediated synaptic activation, FUS translocates from dendrites of hippocampal 
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neurons into the spines where it is believed to facilitate local translation of actin-
associated proteins, such as Nd1-L, that are necessary to develop spine 
morphology (Fujii and Takumi, 2005).  This hypothesis is supported by the 
abnormal spine morphology and attenuated spine density in hippocampal 
pyramidal neurons derived from FUS -/- mice (Fujii et al., 2005).  Thus by 
regulating aspects of mRNA transport, FUS could affect local translation and 
have significant implications on cell fate. Recently, adenomatous polyposis coli 
(APC)-containing RNA granules, which are located at cell protrusions and may 
mediate cell migration, were shown to contain FUS.  Moreover, translation of 
kank-2 (KN motif and ankyrin repeat domains 2), a component of APC granules, 
was dependent upon FUS expression (Yasuda et al., 2013), further underscoring 
the role of FUS in local translation. 
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FUS IN STRESS RESPONSE AND ALS 
More than 40 mutations in FUS have now been identified to cause ALS 
(Da Cruz and Cleveland, 2011). A majority of these mutations are localized to the 
C-terminal NLS of the protein and result in varying degrees of cytoplasmic 
mislocalization (Bosco et al., 2010a; Dormann et al., 2010; Ito et al., 2010; Gal et 
al., 2011; Kino et al., 2011). While it is still unclear whether these mutations result 
in loss of function(s) or gain-of-toxic function(s), it is somewhat clear that the 
degree of cytoplasmic localization corresponds to the severity of the disease 
(Dormann and Haass, 2013). FUS plays a role in multiple cellular functions such 
as DNA damage repair, transcriptional regulation, mRNA splicing, RNA transport 
and stress response. Thus many pathways could be affected by FUS variants 
that can ultimately lead to disease. Indeed much research is focused on 
investigating how mutations in FUS can affect these pathways. 
The assembly of ALS-linked FUS variants into cytoplasmic puncta called 
stress granules under various conditions of applied stress has also drawn 
considerable attention within the field over the past few years (reviewed in 
(Wolozin, 2012; Bentmann et al., 2013; Li et al., 2013)).  Stress granules are 
stalled translational complexes that form in response to environmental or 
metabolic stress.  The proposed function of stress granules is in the triage of 
mRNAs, dictating their fate for expression, degradation or suppression in order to 
express the appropriate repertoire of proteins to re-establish homeostasis 
(Kedersha and Anderson, 2002).  ALS-linked FUS has consistently been 
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detected within stress granules under conditions of protein over-expression, 
oxidative stress, heat-shock and endoplasmic reticulum (ER)-stress (Bosco et al., 
2010a; Dormann et al., 2010; Gal et al., 2011; Kino et al., 2011; Bentmann et al., 
2012).  Endogenous or ectopically expressed WT-FUS is rarely found in stress 
granules in response to these commonly employed stressors and when reported 
is most often found in a small percentage of cells and/or is a result of over-
expression (Goodier et al., 2007; Andersson et al., 2008; Ito et al., 2010; Kino et 
al., 2011; Kato et al., 2012).  Rather, the association of FUS with stress granules 
correlates with cytoplasmic expression, with ALS-causing variants, such as FUS 
P525L and R495X, exhibiting robust levels of both cytoplasmic mislocalization 
and stress granule incorporation.  Conversely, FUS variants with nuclear 
expression remain nuclear and excluded from stress granules (Bosco et al., 
2010a; Dormann et al., 2010).  The notion that FUS must be in the cytoplasm 
and already “poised” to enter stress granules at the time stress is applied was 
supported by Dormann et al., who demonstrated that WT FUS assembled into 
stress granules only when its expression was restricted to the cytoplasm by 
blocking the nuclear importer transportin (Dormann et al., 2010). 
That only FUS variants robustly incorporate into stress granules under 
conditions of applied stress raises the possibility that FUS variants impair cellular 
stress response in ALS. While there is no functional assay per se for stress 
granules, Baron et al demonstrated that the presence of FUS variants in stress 
granules altered several properties that may be important for stress granule 
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function (Baron et al., 2013).  Under conditions of sodium arsenite (an inducer of 
oxidative stress), the expression of FUS variants delayed the assembly and 
expedited the disassembly of stress granules.  Moreover, FUS variants increased 
the dynamics of stress granules as measured by FRAP (fluorescence recovery 
after photobleaching).  These observations are consistent with a destabilizing 
effect of FUS variants on stress granules.  Interestingly, the size and abundance 
of stress granules were enhanced by FUS variants, which may be an outcome of 
the increased protein- and/or mRNA-load that is sequestered into these 
structures by FUS variants (Baron et al., 2013).  Intriguingly, stress granule 
marker proteins have been detected in pathological aggregates of post-mortem 
tissues from individuals with ALS and FTLD (Dormann et al., 2010; Liu-
Yesucevitz et al., 2010; Bentmann et al., 2013), suggesting that these granules 
may accumulate during chronic stress and thus serve as precursors to the end-
stage pathological aggregates seen in these disorders (Wolozin, 2012).  
Stress granules are composed of many (>50) RNA-binding proteins that 
contain aggregation-prone domains, including “low complexity”, “prion-like” 
domains (Anderson and Kedersha, 2008; Kato et al., 2012; Li et al., 2013).  This 
domain in FUS (residues 1- ~165) was shown to facilitate aggregation in yeast 
(Sun et al., 2011) and to drive the association of FUS with hydrogels, a 
biomaterial that is composed of amyloid-like fibrils and that has been proposed to 
mimic the physicochemical properties of stress granules (Han et al., 2012; Kato 
et al., 2012).  Kato et al., and Han et al., demonstrated that modifications to the 
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prion-like domain of FUS prevented the association of FUS with hydrogels and 
stress granules in cell culture (Han et al., 2012; Kato et al., 2012), which is at 
odds with other reports demonstrating a minimal contribution of this domain for 
the assembly of ALS-FUS variants into stress granules (Bentmann et al., 2012; 
Baron et al., 2013).  Bentmann et al., and Baron et al., show that the C-terminal 
RGG-rich regions of FUS are the most important for association with stress 
granules. The methylation of arginine residues is another factor that may 
modulate the assembly of FUS into stress granules.  Arginine residues within the 
RGG domains of FUS are hypermethylated (Rappsilber et al., 2003), and 
methylated FUS was detected in post-mortem aggregates of ALS patient tissues 
(Dormann et al., 2012).  However, Baron et al., demonstrated that methylation of 
FUS was not a prerequisite for stress granule incorporation under sodium 
arsenite stress (Baron et al., 2013).  A key question that awaits further 
exploration is whether FUS is being recruited to stress granules through 
interactions with proteins, RNA or both types of molecules.   
While the dogma in the stress granule field indicates that translation is 
silenced in stress granules (Kedersha and Anderson, 2002), a recent report 
demonstrating that FUS is present in translationally active RNA granules 
(Yasuda et al., 2013) raises the intriguing possibility that FUS variants may 
inappropriately turn on translation in stress granules under conditions of stress.  
To date, however, there is no evidence that FUS variants actually influence 
protein translation in either direction (i.e., repression vs upregulation) under 
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conditions of stress. 
The various and diverse functions of FUS may ultimately all be involved in 
the role of FUS in response to stress.  Cells experience many endogenous and 
exogenous stimuli and stressors on a regular basis. Therefore, there exist 
specific pathways and processes within a cell that elicit quick and effective 
responses to help maintain cellular homeostasis.  The role of FUS in stress 
response is a new area of research and is the main topic of this thesis, to be 
discussed in greater detail in Chapters II and III.   
The role of FUS and its ALS-linked variants has been extensively 
examined under stress conditions; however, these conditions have been limited 
to oxidative, ER stress and heat shock. In Chapter II, I have explored the 
response of FUS to hyperosmolar stress and have demonstrated that even WT 
endogenous FUS, which does not respond to any of the aforementioned 
stressors, translocates into the cytoplasm and incorporates into stress granules. 
This is a very specific response to hyperosmolar stress, since FUS remains 
nuclear under other stress conditions tested (oxidative stress, ER stress and heat 
shock). Furthermore, I have demonstrated that FUS plays a prosurvival role 
under hyperosmolar conditions because reduction of FUS decreased the cell 
viability under such conditions.  
While it is clear that mutations in FUS result in mislocalization of the 
protein to the cytoplasm, it is still not clear what other fundamental properties of 
FUS are affected by mutations that may contribute to disease. I demonstrate that 
 24 
 
mutations alter the structure of FUS and result in protein misfolding. The 
misfolded FUS proteins, in turn, inhibit fast axonal transport in anterograde and 
retrograde directions. I have shown that the inhibition is mediated by stress-
activated p38 MAP kinase. Finally, I have shown the evidence for aberrant p38 
MAP kinase regulation in ALS patients. Take all together, my work demonstrates 
that FUS has a role in cellular stress response and perturbations to its structure 
caused by genetic mutations results in pathogenic effects. 
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Preface to Chapter II 
 
A large part of the work presented in this chapter was performed by Reddy 
Ranjith K Sama (RRKS) with the exceptions below: 
 Immunofluorescence experiments were performed by RRKS and Nathan Lemay. 
Confocal imaging and analysis was performed by Laura Kaushansky. Stable 
NSC34 cells were prepared by Shinsuke Ishigaki and Fumihiko Urano. MTT 
assays and analysis were performed by RRKS and Catherine Ward.  
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ABSTRACT 
 
FUsed in Sarcoma/Translocated in LipoSarcoma (FUS/TLS or FUS) has been 
linked to several biological processes involving DNA and RNA processing, and 
has been associated with multiple diseases, including myxoid liposarcoma and 
amyotrophic lateral sclerosis (ALS).  ALS-associated mutations cause FUS to 
associate with stalled translational complexes called stress granules under 
conditions of stress.  However, little is known regarding the normal role of 
endogenous (non-disease linked) FUS in cellular stress response.  Here, we 
demonstrate that endogenous FUS exerts a robust response to hyperosmolar 
stress induced by sorbitol. Hyperosmolar stress causes an immediate re-
distribution of nuclear FUS to the cytoplasm, where it incorporates into stress 
granules.  The redistribution of FUS to the cytoplasm is modulated by 
methyltransferase activity, whereas the inhibition of methyltransferase activity 
does not affect the incorporation of FUS into stress granules.  The response to 
hyperosmolar stress is specific, since endogenous FUS does not redistribute to 
the cytoplasm in response to sodium arsenite, hydrogen peroxide, thapsigargin, 
or heat shock, all of which induce stress granule assembly.  Intriguingly, cells 
with reduced expression of FUS exhibit a loss of cell viability in response to 
sorbitol, indicating a prosurvival role for endogenous FUS in the cellular response 
to hyperosmolar stress.  
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INTRODUCTION 
Fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is an 
RNA/DNA-binding protein that is implicated in a diverse array of cellular 
processes.  FUS, also known as heterogeneous ribonuclear protein hnRNP P2 
(Calvio et al., 1995), is a member of the FET (previously TET) family of proteins 
that also includes EWS (Ewing’s sarcoma) and TAF15 (TATA-binding protein-
associated factor 15) (Tan and Manley, 2009).  FUS was originally discovered in 
the context of a fusion oncoprotein in myxoid liposarcoma cells (Crozat et al., 
1993).  Since then, this multifunctional protein has been linked to various aspects 
of RNA and DNA-processing, including mRNA splicing (Ishigaki et al., 2012), 
transcription (Wang et al., 2008), and DNA repair (Kuroda et al., 2000).  
Recently, mutations in FUS have been linked to the fatal neurodegenerative 
disease amyotrophic lateral sclerosis (ALS) (Kwiatkowski et al., 2009; Vance et 
al., 2009). 
FUS is predominately expressed in the nucleus of most cells (Andersson 
et al., 2008), although it shuttles between the nucleus and cytoplasm during 
mRNA transport  (Zinszner et al., 1997; Fujii and Takumi, 2005). Several reports 
have shown that ALS-linked FUS variants associate with cytoplasmic stress 
granules under conditions of oxidative stress and heat shock (Bosco et al., 
2010a; Dormann et al., 2010; Gal et al., 2011).  Stress granules are stalled 
translational complexes comprised of mRNA, ribosomes, and RNA-binding 
proteins that form in response to induced stress, such as hyperosmolar stress, 
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oxidative stress, heat shock, ultraviolet irradiation and viral infection (Anderson 
and Kedersha, 2009).  These dynamic complexes are thought to play a role in 
sorting mRNAs for expression, storage or degradation (Kedersha and Anderson, 
2002).  More recently, stress granules have also been shown to directly regulate 
protein activity in the context of cellular signaling (Wippich et al., 2013).  In 
contrast to the aforementioned FUS variants, much less is known about the 
association of endogenous FUS with stress granules and the role of endogenous 
FUS in stress response.   
Herein, we sought to examine the response of endogenous FUS to 
various cellular stressors.  We found that inducers of stress granule assembly 
shown to direct FUS variants into stress granules, such as sodium arsenite, 
thapsigargin, hydrogen peroxide, and heat shock, had no effect on the 
subcellular distribution of endogenous FUS.  In striking contrast, endogenous 
FUS exhibited a robust redistribution from the nucleus to the cytoplasm and 
assembled into stress granules under conditions of hyperosmolar stress induced 
by sorbitol, mannitol, sucrose, sodium chloride, and polyethylene glycol (PEG).  
Not only was the response of FUS stress-specific, it was also regulated by 
methyltransferase activity.  Cells with reduced FUS expression were more 
susceptible to sorbitol-induced toxicity, suggesting that FUS plays protective role 
with regard to cellular homeostasis.  These data establish a novel role for the 
multifunctional FUS protein in cellular stress response. 
 
 30 
 
RESULTS 
Endogenous FUS redistributes to the cytoplasm and assembles into stress 
granules in response to hyperosmolar stress.   
In order to investigate the role of FUS in stress response, we examined 
the nucleo-cytoplasmic distribution of FUS in response to various cellular 
stressors.  Hyperosmolar stress induced by the administration of 0.4 M sorbitol to 
HeLa cells for 1 h resulted in a striking redistribution of FUS from the nucleus to 
the cytoplasm, where FUS assembled into numerous puncta. A majority of FUS-
positive puncta co-localized with the stress granule marker proteins, G3BP (Fig. 
2.1A) and TIAR (Fig. 2.1B) (Kedersha and Anderson, 2007).  Since stress 
granules are functionally related to processing bodies (P-bodies), which are 
cellular sites of mRNA degradation (Moore, 2005), we also probed for the co-
localization of endogenous FUS with GE-1/hedls, a constituent of P-bodies but 
not stress granules (Kedersha and Anderson, 2007).  The majority of P-bodies 
did not co-localize with FUS-positive granules.  However, some P-bodies 
appeared to associate with and/or dock onto FUS-positive granules (Fig. 2.1C), 
consistent with the physical association between P-bodies and stress granules 
that has been previously described (Kedersha et al., 2005; Bosco et al., 2010a).  
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Figure 2.1 
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Figure 2.1 Endogenous FUS redistributes to the cytoplasm and localizes to 
cytoplasmic stress granules in response to sorbitol.  
Confocal images of untreated HeLa cells (top row in each panel) as compared to 
cells treated with 0.4 M sorbitol for 1 h (bottom row in each panel; A–C) are 
shown. Cells probed with an anti-FUS antibody (green) and either the stress 
granule marker anti-G3BP (A) or anti-TIAR (B) revealed that FUS co-localizes 
with stress granules in response to sorbitol. C) P-bodies were detected by anti-
GE-1/hedls antibody in both untreated and treated conditions; however, the 
majority of P-bodies did not exhibit co-localization with FUS. Cells were counter 
stained with the nuclear marker DAPI (blue; A–C). Images are representative of 
at least n = 3 experiments. Scale bar represents 10 µm. 
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The redistribution and incorporation of FUS into stress granules in 
response to sorbitol is reminiscent of other nuclear hnRNPs, such as hnRNP A1 
(Guil et al., 2006) and TDP-43 (Dewey et al., 2010).  However, not all hnRNP 
proteins redistribute to stress granules in response to sorbitol (van der Houven 
van Oordt et al., 2000), suggesting a functional role in stress response for those 
hnRNPs that do localize to these structures.  In addition to sorbitol, hyperosmolar 
stress induced by mannitol, sucrose, sodium chloride, PEG3350 and PEG8000 
also caused FUS to redistribute to the cytoplasm and incorporate into stress 
granules (Fig. 2.2). Thus the response of FUS is a more generalized response to 
hyperosmolar conditions and not specific to sorbitol treatment. 
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Figure 2.2 
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Figure 2.2 Endogenous FUS responds to hyperosmolar stress 
HeLa cells untreated (top row) or treated with 300 mM sucrose, 0.2 M sodium 
chloride (NaCl), 0.4 M mannitol, 20% polyethylene glycol (PEG)–3350 or 20% 
PEG–8000 for 1 h were fixed and imaged. Cells probed with anti-FUS (green) 
and anti-G3BP antibodies revealed that FUS co-localized with stress granules in 
response to all the hyperosmolar stress inducing agents. Cells were counter 
stained with the nuclear marker DAPI (blue). Images are representative of at 
least n=3 experiments. Scale bar represents 10 μm. 
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Next, we investigated the effect of sorbitol in additional cell lines.  
Administration of sorbitol to HEK (human embryonic kidney)-293T, MEFs (mouse 
embryonic fibroblasts) and NSC-34 (neuroblastoma x spinal cord hybrid) 
(Cashman et al., 1992) cell lines recapitulated the results from HeLa cells; FUS 
redistributed from the nucleus to the cytoplasm, where it assembled into G3BP- 
and TIAR-positive stress granules (Fig. 2.3).   Therefore, the response of FUS to 
hyperosmolar stress is not a cell type- or species-specific phenomenon, but 
rather is detected in several different mammalian cell lines.   
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Figure 2.3 
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Figure 2.3 The response of FUS to sorbitol is recapitulated in several 
mammalian cell lines.  
HEK-293 (A), MEF (B) and NSC-34 (C) cells were either untreated (top row in 
each panel) or treated (bottom row in each panel) with 0.4 M sorbitol for 1 h. 
Immunofluorescence with anti-FUS (green) and anti-G3BP (A) or anti-TIAR (B 
and C) antibodies showed that FUS localized to stress granules in response to 
sorbitol in all three cell lines. Cells were counter-stained with the nuclear marker 
DAPI (blue; A-C). All images are representative of n=3 independent experiments. 
Scale bar represents 10 μm. 
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In contrast to sorbitol and other hyperosmolar stress conditions, FUS did 
not redistribute to the cytoplasm when HeLa cells were exposed to inducers of 
oxidative stress (e.g., sodium arsenite and hydrogen peroxide), endoplasmic 
reticulum (ER) stress (e.g., thapsigargin) or heat shock, all of which induce the 
formation of stress granules in a majority of cells (Fig. 2.4) (Kedersha and 
Anderson, 2007; Emara et al., 2012). Endogenous FUS was not detected in any 
of the G3BP-positive stress granules that formed under these conditions; we did 
not detect any cells with elevated cytoplasmic FUS or FUS-positive stress 
granules under these conditions. Similarly, exogenously expressed wild-type 
FUS did not redistribute nor assemble into stress granules under the 
aforementioned conditions (Bosco et al., 2010a; Dormann et al., 2010; Bentmann 
et al., 2012; Daigle et al., 2013), although the effect of sorbitol on endogenous or 
exogenous FUS has not been reported.  Thus our results demonstrate that the 
formation of stress granules by general stressors is not sufficient to cause a 
redistribution of FUS to the cytoplasm, indicating that there are specific factors 
associated with hyperosmolar stress that elicit this response for endogenous 
FUS. 
 
 
 
 
 
 40 
 
 
 
Figure 2.4 
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Figure 2.4 The recruitment of FUS to cytoplasmic stress granules is stress-
specific.  
HeLa cells were treated with either 0.5 mM sodium arsenite (NaAsO2) for 1 h, 
1.5 mM hydrogen peroxide (H2O2) for 2 h, 50 µM thapsigargin for 30 min, or heat 
shock at 43° C for 30 min. Immunofluorescence revealed that G3BP-positive 
stress granules (red) formed under all stress conditions. FUS (green) remained 
nuclear and absent from stress granules under these stress conditions, similar to 
the unstressed condition (top part). Nuclei were stained with DAPI (blue). All 
images are representative of n = 3 independent experiments. Scale bar 
represents 10 µm. 
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The assembly of FUS into stress granules is rapid and reversible.   
The formation of stress granules represents a fast, almost immediate, 
response of cells to induced stress.  To determine the time frame in which FUS 
responds to sorbitol, we monitored the cellular redistribution of FUS by 
immunofluorescence microscopy over a one-hour time course of sorbitol 
exposure.  G3BP is an effector of stress granule assembly (Tourriere et al., 2003; 
Aulas et al., 2012) and was therefore used as a marker to monitor the assembly 
process. The cytoplasmic redistribution of FUS was detected within 10 min of 
sorbitol treatment, a time point that preceded the appearance of discreet G3BP-
positive cytoplasmic foci, demonstrating that FUS starts to accumulate in the 
cytoplasm before stress granules are fully formed (Fig. 2.5A).  Within 20 min of 
sorbitol treatment, discreet G3BP-positive stress granules containing FUS were 
detected. Therefore FUS appears to incorporate into stress granules on the 
same time scale that these foci are being formed.  G3BP- and FUS-positive 
stress granules appear fully formed by 60 min, at which time a substantial 
fraction of FUS was redistributed to the cytoplasm.  
 The formation of stress granules is a reversible process (Anderson and 
Kedersha, 2008).  After the induced stress is removed, stress granules 
disassemble as the cell re-establishes homeostasis.  We monitored the 
disassembly of stress granules in HeLa cells pre-treated with sorbitol to 
determine the subcellular fate of FUS as cells re-established homeostasis.  The 
disassembly of stress granules was initiated by replacing media containing 
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sorbitol with fresh media lacking sorbitol, and cells were monitored for 60 min by 
immunofluorescence microscopy as described above.  Within 10 min of removing 
sorbitol from the media, FUS dissociated from stress granules and re-distributed 
to the nucleus in virtually all (~90%) cells.  However, G3BP-positive, FUS-
negative foci persisted in approximately one third of cells at this time point (Fig. 
2.5B).  For the remainder of the time course, FUS was localized to the nucleus 
while G3BP-positive stress granules gradually continued to disassemble until the 
60 min time point, when ~20% of cells contained G3BP-positive stress granules.  
These data show that FUS exhibits a rapid response not only to the 
administration of sorbitol (Fig. 2.5A), but also to the removal of this stressor (Fig. 
2.5B). 
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Figure 2.5 
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Figure 2.5 The response of FUS to sorbitol is rapid and reversible.  
A) A representative time-course for the cytoplasmic redistribution of FUS into 
stress granules upon exposure to hyperosmolar stress. HeLa cells were treated 
with 0.4 M sorbitol for the indicated time points, fixed, and assessed by 
immunofluorescence with anti-FUS (green) and anti-G3BP (red) antibodies, and 
the nuclear marker DAPI (blue). Elevated levels of cytoplasmic FUS were 
detected as early as 10 min. FUS accumulated into discreet stress granules by 
20 min. The nucleo-cytoplasmic distribution of FUS continued to shift towards the 
cytoplasm over the remaining time course. B) A representative time-course for 
the return of FUS to the nucleus and the concomitant disassembly of stress 
granules upon withdrawal of sorbitol. HeLa cells were treated with 0.4 M sorbitol 
for 1 h, after which the sorbitol was replaced with fresh media and the cells were 
processed as described in (A). A majority of FUS re-localized to the nucleus 
within 10 min. Some G3BP positive stress granules persisted for up to 1 h. 
Images are representative of at least n = 3 experiments. Scale bar represents 
10 µm. 
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Stress granule assembly is required for robust cytoplasmic redistribution 
of FUS.   
FUS is a nucleo-cytoplasmic shuttling protein.  Therefore, the 
accumulation of FUS in the cytoplasm can result from increased export of the 
protein from the nucleus and/or decreased import to the nucleus from the 
cytoplasm.  The nucleo-cytoplasmic equilibrium of FUS may be shifted towards 
the cytoplasm through FUS binding interactions.  For example, injection of anti-
FUS antibodies into cells trapped the majority of FUS in the cytoplasm within 2 h 
(Zinszner et al., 1997).  Since the timescale of FUS redistribution from the 
nucleus to the cytoplasm under conditions of hyperosmolar stress (1 hour, Fig. 
2.5) is similar to that in aforementioned antibody study (2 hours, (Zinszner et al., 
1997)), we asked whether or not stress granules serve as a “cytoplasmic sink” 
that effectively traps FUS in the cytoplasm through mass action. Stress granule 
assembly was inhibited by the addition of 50 g/mL emetine, which stabilizes 
polysomes and blocks translation elongation (Kedersha et al., 2000), for 1 h prior 
to the administration of hyperosmolar stress. As expected, only diffuse G3BP 
signal (i.e., no G3BP-positive stress granules) was observed under these 
conditions (Fig 2.6). Interestingly, emetine treatment also markedly reduced the 
cytoplasmic redistribution of FUS (Fig. 2.6) in the presence of sorbitol.  These 
data implicate stress granule formation as a requisite for the cytoplasmic 
redistribution of FUS, and suggest that the full response of FUS to hyperosmolar 
stress includes its assembly into stress granules.  
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Figure 2.6 
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Figure 2.6 An inhibitor of stress granule assembly prevents the 
cytoplasmic redistribution of FUS.  
HeLa cells were treated with 0.4 M sorbitol for 1 h, 50 µg/mL emetine for 1 h or 
pre-treated with emetine followed by sorbitol treatment. Cells were then fixed and 
probed by immunofluorescence for DAPI (blue), FUS (green), and G3BP (red). 
Emetine pre-treatment inhibited both stress granule assembly, as evidenced by 
the diffuse G3BP signal, and the cytoplasmic redistribution of FUS in the 
presence of sorbitol. All images are representative of at least n = 3 independent 
experiments. Scale bar represents 10 µm. 
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Next we investigated the role of FUS in stress granule assembly under 
conditions of hyperosmolar stress.  HeLa cells were first treated with either 
siRNA specific for FUS or non-targeting siRNA as a control for 48 hrs, and were 
then exposed to 0.4 M sorbitol for 30 min to induce the formation of stress 
granules (Fig. 2.7A).  Although cells treated with FUS siRNA exhibited a ~90% 
reduction in FUS protein levels (Fig. 2.7B), these cells produced G3BP-positive 
stress granules in response to sorbitol that were indistinguishable from control 
cells (Fig. 2.7A).  While the physical response of FUS to hyperosmolar stress 
depends on the formation of stress granules (Fig. 2.6), FUS does not appear to 
dictate the ability of stress granules to form as they are formed even when FUS 
knocked down.  
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Figure 2.7 
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Figure 2.7 FUS is not required for stress granule assembly. 
A) HeLa cells were transfected with non-targeting siRNA (siNT) or siRNA against 
FUS (siFUS) for 48 h and subsequently treated with 0.4 M sorbitol for 1 h. Cells 
were then fixed and probed by immunofluorescence for DAPI (blue), FUS 
(green), and G3BP (red). Cells treated with either siFUS or siNT exhibited normal 
stress granule formation (red) in response to sorbitol, despite a significant 
reduction in FUS protein levels in siFUS treated cells as evidenced by 
immunofluorescence (green) and Western blot (B). All images are representative 
of at least n = 3 independent experiments. Scale bar represents 10 µm. 
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Methylation regulates the nucleo-cytoplasmic distribution of FUS under 
hyperosmolar stress.   
Next we investigated the mechanisms by which FUS relocalizes to the 
cytoplasm and incorporates into stress granules in response to hyperosmolar 
stress.  Methylation of arginine residues is a post-translational modification that 
modulates the nucleo-cytoplasmic distribution of hnRNP proteins, such as the 
cold-inducible RNA-binding protein (CIRP) (De Leeuw et al., 2007).  Some 
reports implicate a link between the arginine methylation status of ALS-linked 
FUS and its subcellular localization (Tradewell et al., 2012; Yamaguchi and 
Kitajo, 2012). In fact, mass spectrometry analyses demonstrate that up to 20 
arginine residues are asymmetrically dimethylated in FUS (Rappsilber et al., 
2003).  That protein arginine N-methyltransferase-1 (PRMT1), which accounts for 
~85% of arginine methylation in the cell (Bedford and Clarke, 2009), and FUS 
interact suggests that the methylation of FUS is catalyzed by PRMT1 (Du et al., 
2011; Tradewell et al., 2012; Yamaguchi and Kitajo, 2012). Interestingly, stress 
granules contain arginine methylated hnRNP proteins, raising the possibility that 
this post-translational modification influences stress granule dynamics (Xie and 
Denman, 2011).  This notion is supported by an attenuation of fragile X mental 
retardation protein (FMRP) in stress granules upon exposure to adenosine-2’, 3’-
dialdehyde (AdOx) (Dolzhanskaya et al., 2006), a general inhibitor of 
methyltransferases (O'Dea et al., 1987).   
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To determine whether or not the methylation status of FUS regulates its 
subcellular localization under conditions of hyperosmolar stress, we examined 
the nuclear-cytoplasmic distribution of FUS after treatment of HeLa cells with 
AdOx.  FUS remained predominantly nuclear in the presence of AdOx alone, 
similar to untreated cells (data not shown).  However, when cells were pre-
treated with AdOx prior to sorbitol exposure, there was a significant effect on the 
nuclear-cytoplasmic partitioning of FUS compared to cells treated with sorbitol 
alone (Fig. 2.8A and B).  While sorbitol treatment resulted in a ~50% reduction of 
nuclear FUS compared to control cells, pre-treatment with AdOx restored ~30% 
of FUS to the nucleus (Fig. 2.8B). To quantify the methylation status of the FUS 
protein itself, FUS was immunoprecipitated from untreated cells or from cells 
treated with AdOx in combination with sorbitol and probed for asymmetrically 
dimethylated arginine residues with the ASYM24 antibody, which recognizes 
proteins that are asymmetrically methylated on arginine residues (Tradewell et 
al., 2012).  Arginine methylation of FUS in untreated cells was detected by 
ASYM24 (Fig. 2.8C), which is expected since FUS is reportedly arginine 
methylated under homeostatic conditions (Rappsilber et al., 2003).  The level of 
methylated FUS was not significantly altered by the addition of sorbitol (data not 
shown).  However, the arginine methylation status of FUS decreased by more 
than 50% in cells pre-treated with AdOx (data not shown) or AdOx in combination 
with sorbitol (Figs. 2.8C and D).  Since AdOx is a general methyltransferase 
inhibitor, we cannot exclude the possibility that other methylation events 
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influence the subcellular distribution of FUS in these experiments.  Nonetheless, 
these data suggest that the methylation status of FUS must be maintained in 
order for it to redistribute to the cytoplasm under conditions of hyperosmolar 
stress, and are consistent with the notion that hypomethylated forms of FUS fail 
to shuttle out of the nucleus (Tradewell et al., 2012; Yamaguchi and Kitajo, 
2012).  
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Figure 2.8 
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Figure 2.8 Methylation regulates the nucleo-cytoplasmic distribution of 
FUS.  
A,B) HeLa cells were treated with 0.4 M sorbitol for 1 h, or pre-treated with 50 µM 
AdOx for 24 h prior to sorbitol treatment (AdOx + sorbitol) and subjected to 
confocal immunofluorescence imaging with anti-FUS (green) and anti-G3BP 
(red) antibodies. Sorbitol decreased the percentage of cellular FUS in the 
nucleus from 90 ± 5.1% in untreated cells to 46.5 ± 9.8%. Pre-treatment of cells 
with AdOx prior to sorbitol increased the percentage of cellular FUS in the 
nucleus to 75.6 ± 7.4%. Data shown are the average of three independent 
experiments ± standard deviation. Statistical significance was determined by 
ANOVA and Tukey's post hoc pairwise test (**P < 0.005, ***P < 0.0005). No other 
comparisons were statistically significant. Scale bar represents 10 μm. C) FUS 
was immunoprecipitated from untreated HeLa cells or from AdOx + sorbitol cells 
and probed with the ASYM24 antibody by Western blot. FUS was used as a 
loading control. D) Densitometry analysis of (C) revealed a 68.6 ± 7.8% decrease 
in the amount of FUS that is arginine dimethylated when cells were pre-treated 
with AdOx compared to untreated cells. Data shown are the average of three 
independent experiments ± standard deviation. Statistical significance was 
determined by Student's t-test (**P < 0.005). 
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Next we sought to determine if hypomethylated FUS could still assemble 
into stress granules.  Since the assembly of FUS into stress granules occurs 
concomitantly with cytoplasmic accumulation (Fig. 2.5), it was necessary to first 
dissect these two processes.  To this end, we transiently transfected HeLa cells 
with the GFP-tagged FUS 515X truncation construct, which lacks the nuclear 
localization signal and is therefore retained in the cytoplasm under homeostatic 
conditions (Bosco et al., 2010a). GFP-FUS 515X assembled into stress granules 
in response to 0.4 M sorbitol, and the extent of this association was the same 
whether cells were pre-treated with AdOx or not (Figs. 2.9A and B).  The same 
outcome was observed in HEK-293 cells stably expressing GFP-FUS 515X (data 
not shown).  In contrast to the GFP-FUS signal, there was a dramatic decrease 
in the ASYM24 signal in cells pre-treated with AdOx (Figs. 2.9A and B), 
indicating that pre-treatment with AdOx effectively inhibited methyltransferase 
activity within these cells.  Immunoprecipitation with anti-GFP followed by 
western blot analysis with the ASYM24 antibody confirmed that GFP-FUS 515X 
was indeed hypomethylated due to AdOx pre-treatment (Fig. 2.9C).  Thus, 
despite a large reduction in the methylation status of FUS in AdOx pre-treated 
cells (Figs. 5 and 6), FUS still robustly associated with stress granules. We note 
that a small fraction of FUS remained dimethylated in the AdOx condition (Fig. 
2.9C), presumably FUS protein that was methylated prior to AdOx exposure but 
had not turned over during the course of the experiment (Xie and Denman, 
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2011).  In the absence of commercially available antibodies that are specific for 
dimethylated FUS, we cannot exclude the possibility that stress granules contain 
some dimethylated FUS in these experiments.  However, the dramatic decrease 
in ASYM24 signal is consistent with a reduced load of methylated proteins within 
stress granules, and therefore it is unlikely that all of the residual methylated FUS 
is sequestered into these structures.   Together, these studies argue against a 
role for arginine methylation in regulating the incorporation of FUS in stress 
granules.   
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Figure 2.9 
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Figure 2.9 Methylation does not regulate the incorporation of FUS into 
stress granules.  
HeLa cells were transiently transfected to express GFP-FUS G515X. Cells were 
exposed to 0.4 M sorbitol for 1 h either (A) in the absence of AdOx or (B) after 
cells had been pre-treated with 25 µM AdOx for 8 h. A) Confocal imaging showed 
that GFP-FUS G515X (green) assembles into G3BP-positive stress granules 
(red) upon sorbitol treatment (top panel). Co-staining with the ASYM24 antibody 
(a far-red fluorescence probe was employed; green is used in the images for 
clarity) revealed that these same stress granules contained asymmetrically 
dimethylated proteins (bottom panel). B) While the ASYM24 signal is dramatically 
decreased within stress granules and cells pre-treated with AdOx (bottom panel), 
there is still a robust association of GFP-FUS with stress granules under the 
same conditions (top panel). Scale bar represents 10 µm. C) Immunoprecipitation 
of GFP-FUS G515X with an anti-GFP antibody and a subsequent Western blot 
analysis with ASYM24 revealed that FUS is hypomethylated due to AdOx 
pretreatment. The ratio of the ASYM24 signal intensity to that of GFP was 
determined by densitometry and normalized to the untreated condition. Ratios 
are shown below the blot for each condition. All data are representative of n = 3 
independent experiments. 
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Cells are susceptible to sorbitol toxicity and death when FUS expression is 
reduced.   
Given that the full response of FUS to hyperosmolar stress includes its 
assembly into stress granules, and that the role of stress granules is to overcome 
stress and re-establish cellular homeostasis, we investigated whether the 
expression of FUS is important for cellular viability under conditions of 
hyperosmolar stress.  The normal cellular response to hyperosmolar stress 
includes cell cycle arrest, during which time cells may adapt to stress and 
resume proliferation (Burg et al., 2007).  However, severe hyperosmolar stress 
induces apoptosis and cell death (Burg et al., 2007; Bevilacqua et al., 2010). To 
address the susceptibility of cells to hyperosmolar toxicity in the absence of FUS, 
we employed inducible NSC-34 cell lines that stably express either shRNA 
specific for FUS (shFUS) or a scrambled control shRNA (shSC) sequence.  
These cell lines are advantageous for cell viability measurements since cell 
death resulting from chemical transfection protocols is eliminated.  NSC-34 cells 
were induced with doxycycline for 48 hrs, resulting in ~70% knock down of FUS 
in the shFUS line (Fig. 7A) but not a loss of cell viability in either shFUS or shSC 
cells (data not shown).  Cells were then treated for 8 hrs with either 0.4 M sorbitol 
or 0.25 mM sodium arsenite as a negative control.  Sodium arsenite induces 
stress granule assembly, however endogenous FUS does not associate with 
stress granules under this condition (Fig. 2.4).  Moreover, others have reported 
that mammalian cells with knocked-down FUS expression are not susceptible to 
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sodium arsenite (Aulas et al., 2012).  In agreement with this report, we did not 
detect a difference in percentage cell viability (Fig. 2.10B) or cell death (Fig. 
2.10C) between shFUS and shSC cells in response to sodium arsenite using the 
MTT and LDH assays, respectively.  In contrast, the percentage of viable cells 
was approximately two-fold lower in the shFUS cells compared to shSC cells 
after sorbitol treatment (Fig. 2.10B).  That shFUS cells are more susceptible to 
sorbitol-induced toxicity was confirmed by the LDH cell death assay, which 
revealed 3-fold greater cell death in shFUS cells treated with sorbitol compared 
to shSC cells under the same conditions. Therefore, while the expression of FUS 
is not required for the assembly of stress granules (Fig. 2.7), cellular 
homeostasis and survival during hyperosmolar stress is mediated by the 
expression of FUS. 
.  
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Figure 2.10 
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Figure 2.10 Reduced FUS expression causes cells to become susceptible 
to sorbitol induced toxicity. A) Expression of either a non-targeting scrambled 
shRNA (shSC) or shRNA against FUS (shFUS) was induced by doxycycline for 
48 h in NSC-34 cell lines, resulting in ∼70% knock-down of the FUS protein as 
determined by Western blot. Tubulin was used as a loading control. Cells were 
then treated with 0.4 M sorbitol or 0.25 mM sodium arsenite for 8 h and subjected 
to the (B) MTT cell viability assay or (C) LDH cell toxicity assay. B) A significant 
decrease in cell viability was detected in shFUS cells (38 ± 6%) compared to 
shSC cells (76 ± 11%) when treated with sorbitol, whereas shFUS cells did not 
exhibit an analogous susceptibility to sodium arsenite (59 ± 4% for shFUS vs. 
57 ± 6% for shSC). C) A higher percentage of cell death was detected in shFUS 
cells (15.2 ± 3.6%) compared to shSC cells (4.2 ± 1.4%) in response to sorbitol, 
whereas no difference in cell death was detected when these lines were stressed 
with sodium arsenite (7.4 ± 2.2% for shFUS vs. 4.3 ± 0.7% for shSC). B,C) Data 
shown are an average from n = 3 independent experiments ± standard deviation. 
Statistical significance was determined by Student's t-test (**P < 0.005). 
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DISCUSSION 
Although FUS is predominately expressed in the nucleus of most cell 
types (Andersson et al., 2008), it can shuttle between the nucleus and the 
cytoplasm during mRNA transport (Zinszner et al., 1997; Fujii and Takumi, 2005).  
The equilibrium of FUS expression can be shifted towards the cytoplasm using 
inhibitors against RNA polymerase II (Pol II) (Zinszner et al., 1994) or against the 
nuclear import receptor Transportin-1 (Trp), also known as Karyopherin β2 
(Dormann et al., 2010).  Genetic perturbations of its nuclear localization signal 
(NLS) also increase the cytoplasmic expression of FUS in the neurodegenerative 
disease ALS (Kwiatkowski et al., 2009; Vance et al., 2009). Herein we 
demonstrate a novel and robust response of endogenous FUS to hyperosmolar 
stress, whereby FUS redistributes from the nucleus to the cytoplasm within 
minutes of exposure to sorbitol (Fig. 2.1), mannitol, sodium chloride, sucrose or 
polyethylene glycol (Fig. 2.2).  
A role for FUS in hyperosmolar stress response is further supported by its 
association with stress granules under this condition. Stress granules are stalled 
translational complexes; as such, they are thought to regulate mRNAs 
processing during stress (Anderson and Kedersha, 2008).  Recently, the activity 
of mTORC1 was shown to correlate with its sequestration inside stress granules, 
suggesting that these complexes can also regulate cell signaling at the protein 
level (Wippich et al., 2013).  Importantly, no other chemical or environmental 
stressor has been shown to cause endogenous FUS to redistribute from the 
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nucleus into the cytoplasm and enter into stress granules.  While different 
stressors, such as oxidative stress and heat shock, have been shown to 
influence the association of ALS-linked FUS variants with stress granules, the 
nature of the NLS mutations causes FUS to accumulate in the cytoplasm 
irrespective of stress (Bosco et al., 2010a; Dormann et al., 2010).  In contrast, 
hyperosmolar stress triggers both the cytoplasmic redistribution of FUS and its 
assembly into stress granules.  Therefore, the response of endogenous FUS to 
hyperosmolar stress represents an altogether different mechanism compared to 
the previously described FUS variants.  Furthermore, our data support a normal 
and important role for endogenous FUS in stress response (discussed further 
below), whereas the association of ALS-linked FUS with stress granules is 
thought represent a pathogenic mechanism in disease (Wolozin, 2012).   
 In order to dissect the processes governing the cytoplasmic redistribution 
of FUS from its incorporation into stress granules, we employed the GFP-FUS 
G515X construct, which lacks the nuclear localization domain.  This allowed us to 
investigate the role of methylation as a post-translational modification in both 
events. Inhibition of methyltransferases with AdOx significantly reduced the 
cytoplasmic redistribution of FUS during hyperosmolar stress (Fig. 2.8).  
Moreover, analysis with the ASYM24 antibody revealed that FUS is 
asymmetrically dimethylated at arginine residues under homeostatic conditions 
but is hypomethylated in the presence of AdOx (Figs. 2.8 and 2.9).  These 
observations, together with a mass spectrometry study demonstrating that ~20 
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arginine residues within FUS are asymmetrically dimethylated (Rappsilber et al., 
2003), supports the possibility that methylation of the FUS protein itself dictates 
its subcellular localization during hyperosmolar stress.  Conversely, the 
methylation status of FUS, or other cellular factors for that matter, does not 
appear to regulate the association of FUS with stress granules (Fig. 2.9).  A 
remaining possibility is that other post-translational modifications of FUS 
influence its association with stress granules.  
What are the biological implications of FUS in hyperosmolar stress 
response? Hyperosmolar stress is implicated in a myriad of disease conditions in 
humans, including renal failure, diabetes, neurodegeneration and inflammation, 
as well as disorders of the eye, heart and liver (Brocker et al., 2012).  Moreover, 
the cell shrinkage caused by hyperosmolar stress triggers many adverse 
subcellular events, such as mitochondrial depolarization, inhibition of DNA 
replication and transcription, damage to DNA and proteins, and cell cycle arrest, 
all of which can ultimately lead to cell death (Alfieri and Petronini, 2007; Burg et 
al., 2007; Brocker et al., 2012).   
Our results are consistent with a prosurvival mechanism for endogenous 
FUS in human conditions that involve hyperosmolar stress.  First, the response 
to hyperosmolar stress is specific, since alternative stressors that induce stress 
granule assembly such as oxidative stress and heat shock fail to elicit a similar 
response from endogenous FUS (Figs. 2.4). This data suggests a potentially 
distinct cellular response to hyperosmolar conditions compared to other 
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stressors. Second, cells are more susceptible to hyperosmolar toxicity when FUS 
expression is reduced (Fig. 2.10), supporting a prosurvival role for FUS in this 
type of stress response.  
Other nuclear hnRNPs, such as hnRNP A1, also respond to hyperosmolar 
stress by redistributing to the cytoplasm and assembling into stress granules. 
When localized to stress granules, hnRNP A1 is thought to specifically suppress 
the translation of anti-apoptotic factors and in turn initiates apoptosis under 
conditions of severe hyperosmolar stress (Bevilacqua et al., 2010).  An intriguing 
possibility is that FUS sequesters specific mRNAs and proteins into stress 
granules, thereby altering their expression and/or function in response to the 
hyperosmolar stress.  Indeed, recent PAR-CLIP (Hoell et al., 2011) and RIP-Chip 
(Colombrita et al., 2012)  analyses have identified thousands and hundreds, 
respectively, of mRNA transcripts that are bound by FUS in the cell under 
homeostatic conditions.  Interestingly, FUS binds mRNA that encodes genes 
involved in DNA damage repair and cell cycle regulation (Colombrita et al., 
2012), two pathways that are altered during hyperosmolar stress (Burg et al., 
2007).   
In summary, our results support a prosurvival function for endogenous 
FUS during hyperosmolar stress.  These findings have implications for human 
disorders with an etiology that involves hyperosmolar stress.  Identifying the 
factors that regulate the response of FUS to hyperosmolar stress, as well as the 
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pathways affected by FUS under this stress condition, will be critical to further 
our understanding of this prosurvival role of FUS.  
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MATERIALS AND METHODS 
Cell culture and induced stress 
HeLa cells and HEK293 cells were cultured in minimal essential medium 
(MEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine 
serum (FBS, Sigma, St. Louis, MO, USA) and 1% penicillin and streptomycin 
(P/S, Gibco, Grand Island, NY, USA) under standard culture conditions (37°C, 
5% CO2/95% air).  NSC-34 cells and mouse embryonic fibroblasts (MEFs) were 
cultured in Dulbecco’s MEM (DMEM, Gibco, Grand Island, NY, USA) 
supplemented with 10% FBS and 1% P/S under standard culture conditions. 
FlpIn HEK293 cells with stably integrated GFP-FUS G515X were cultured as 
described previously (Bosco et al., 2010a). Sorbitol, mannitol (Sigma, St. Louis, 
MO, USA), PEG-3350 and PEG-8000 (Fisher Scientific, Pittsburgh, PA, USA) 
were dissolved directly into the media to obtain the  indicated final concentrations 
and added to the cells (Kedersha and Anderson, 2007). Sucrose (Electron 
Microscopy Sciences, Fort Washington, PA, USA) was dissolved into media to 
obtain a final concentration of 600 osmol/L and added to the cells (Bevilacqua et 
al., 2010).  Stock solutions of 100 mM sodium arsenite (Sigma, St. Louis, MO, 
USA) in DMSO (Sigma, St. Louis, MO, USA), 10 mM thapsigargin (Sigma, St. 
Louis, MO, USA) in DMSO, 1 M hydrogen peroxide (Sigma, St. Louis, MO, USA) 
in media, 30 mM emetine (Sigma, St. Louis, MO, USA) in water, 20 mM 
Adenosine-2′,3′-dialdehyde (AdOx, Sigma, St. Louis, MO, USA) in water and 5 M 
sodium chloride (Fisher Scientific, Pittsburgh, PA, USA) in water were prepared 
 71 
 
and added to the media to obtain the final concentrations of 0.5 mM, 50 µM, 1.5 
mM, 50 µg/mL, 50 µM and 0.2 M respectively.  Doxycycline (Sigma, St. Louis, 
MO, USA) was used at a final concentration of 1 µg/mL from a stock of 50 mg/mL 
prepared in water. Cells were exposed to heat shock by adding media, pre-
warmed to 43°C, followed by immediate transfer to an incubator set to 43°C. ON-
TARGETplus SMARTpool (Dharmacon, Waltham, MA, USA ) consisting of a pool 
of siRNAs against FUS (Cat # L-009497-00-0005,) and ON-TARGETplus Non-
targeting pool siRNA (Cat # D-001810-10-05) as control were transfected using 
Lipofectamine-2000 (Invitrogen, Grand Island, NY, USA) according to the 
manufacturer’s instructions.  
NSC-34 cell lines were a kind gift from Dr. Neil Cashman (University of 
British Columbia). Stable NSC-34 cell lines expressing short hairpin (sh) RNA 
against mouse FUS (shFUS) or non-targeting scrambled RNA (shSC) were 
prepared by first transducing with the Tet repressor.  A single clone that 
demonstrated good induction without any leaky expression was then selected. 
NSC34-TetR cells were then transduced with inducible lentivirus-Tet-on/shFUS 
or Tet-on/shSC (Ishigaki et al., 2012).  Cells were treated with 1 µg/mL 
doxycycline to induce the expression of the shRNAs.  
Immunofluorescence  
Immunofluorescence was performed as described in (Bosco et al., 2010a). 
Primary antibody incubation conditions were as follows: 1:500-1000 rabbit anti-
FUS (A300-293A, Bethyl Labs, Montgomery, TX, USA); 1:2500 mouse anti-TIAR 
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(610352, BD Transduction Labs, San Jose, CA, USA); 1:1500 rabbit ant-
ASYM24 (07-414, Millipore, Billerica, MA, USA); 1:2500 mouse anti-G3BP 
(611126, BDTransduction Labs, San Jose, CA, USA) for 1 hr at room 
temperature; and 1:250 mouse anti-GE-1/hedls/p70 S6 kinase (sc-8418, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) for 12 hrs at 4°C. Secondary anti-
mouse IgG antibody conjugated to Dylight 549 (715-505-151, Jackson 
ImmunoResearch Labs, West Grove, PA, USA) was used at 1:1500–1:3000. 
Secondary anti-rabbit IgG antibody conjugated to Dylight 488 (711-485-152, 
Jackson ImmunoResearch Labs, West Grove, PA, USA) and secondary anti-
rabbit IgG antibody conjugated to Cy5 (711-175-152, Jackson ImmunoResearch 
Labs, West Grove, PA, USA) were used at 1:1500–1:3000. GFP signal was 
enhanced using 1:2000 Alexa Fluor 488-conjugated rabbit anti-GFP (A21311, 
Invitrogen, Grand Island, NY, USA). Nuclei were stained with 50 nM 4’,6’-
diamidine-2-phenylindole dihydrochloride (DAPI; D1306, Invitrogen, Grand 
Island, NY, USA) for 5 min at room temperature. Coverslips were mounted with 
ProLong Gold Antifade Reagent (P36930, Invitrogen, Grand Island, NY, USA).  
Image acquisition and quantification 
Fixed cell images were acquired using a Solamere Technology 
Group CSU10B (Salt Lake City, UT, USA) spinning disk confocal system as 
described (Bosco et al., 2010a) or using a Leica DMI6000B microscope (Leica 
Microsystems, Buffalo grove, IL, USA).  For images acquired with the Leica 
microscope, a 100x objective was used with LAS AF One Software (Leica 
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Microsystems, Buffalo Grove, IL, USA) and the Leica DFC365FX 
camera. Maximum projection images were created from acquired image stacks 
(z=0.2-0.25µm, n=6-44 planes) and analyzed using NIH Image J software. 
For quantifying the percentage (%) of nuclear FUS, image stacks 
(z=0.2µm, n=13 planes) of 60 cells were collected from n=3 experiments with the 
spinning disk confocal system above.  Images were analyzed using MetaMorph 
software (Molecular Devices, Sunnyvale, CA, USA). Sum projections of each 
image stack were created after subtracting the background signal as described 
(Bosco et al., 2010a). The integrated morphometry analysis tool was used to 
calculate the percent (%) nuclear FUS. Statistical significance between 
conditions was determined by an ANOVA and Tukey’s post-hoc pairwise test. 
Western blots  
Western blots were performed essentially as described previously (Bosco 
et al., 2010a). Briefly, blots were incubated at 4°C with shaking overnight in the 
presence of primary antibodies as per the following dilutions: 1:500 anti-tubulin 
(Sigma, St. Louis, MO, USA), 1:500 anti-FUS (in house antibody created against 
264-284 peptide sequence of FUS, Genscript, Piscataway, NJ, USA), 1:500 anti-
FUS (47711, Santacruz, Santa Cruz, CA, USA) and 1:1000 anti-ASYM24 (07-
414, Millipore, Billerica, MA, USA). Densitometry was performed using the 
Odyssey infrared imaging systems software (Licor Biosciences, Lincoln, NE, 
USA). 
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Immunoprecipitation   
Cells resuspended in 50 mM Tris HCl (pH 7.5) supplemented with 1% NP-
40, 150 mM NaCl, 5 mM EDTA, 10% glycerol and complete protease inhibitor 
(lysis buffer) were briefly sonicated and incubated at 4°C with shaking for 30 min. 
The lysates were centrifuged for 15 min at 13000 rpm and 4°C.  Pre-clearing of 
the supernatants was achieved by incubation with 100 µL of Biomag Protein G 
beads (Invitrogen, Grand Island, NY, USA) at 4°C with shaking for 2 hrs. The 
beads were removed with a magnet and the protein concentration of the 
supernatant was determined using a bicinchoninic assay (ThermoScientific, 
Billerica, MA, USA). Anti-FUS (Genscript, Piscataway, NJ, USA) or anti-GFP 
antibody (ab290, Abcam, Cambridge, MA, USA) was bound to fresh beads with 
shaking for 2 hrs at 4°C.  A total of 1 mg of the pre-cleared supernatant was then 
added to 100 µL of antibody-bound beads and incubated overnight with shaking 
at 4°C. The lysate was removed and beads were washed three times with lysis 
buffer. Proteins bound to the beads were eluted with 1X SDS sample buffer at 
95°C for 5 min, and probed by western as described above.  
Cell toxicity assays 
NSC-34 cell lines shSC and shFUS were plated in 24 well dishes. 48 hrs 
after induction with doxycyline, cells were treated with 0.4 M sorbitol or 0.25 mM 
sodium arsenite for 8 hrs. For the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide) assay 100 µL of 5 mg/mL MTT (Invitrogen, Grand Island, 
NY, USA)  was added to the wells for 35 min followed by cell lysis overnight with 
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300 μl lysis buffer (10% SDS in 1:1 N,N_-dimethylformamide:water/2% acetic 
acid/2.5% HCl 1 M ) and absorbance measurement at 550 nm using the VICTOR 
V plate reader (Perkin Elmer, Waltham, MA, USA). Cell viability for each sample 
was calculated using the formula: % viability = 100 × (ODSample – 
ODBlank)/(ODUntreated – ODBlank). LDH (Lactate dehyrodenase) assay was 
performed as per manufacturer’s protocol (CytoTox 96® Non-radioactive 
Cytotoxicity Assay, Promega, Madison, WI, USA). After the 8 hr treatment, 50 µL 
of media from each well was transferred to wells of 96 well plate. 50 µL of 
substrate mix was then added to each well and the plates were covered and 
incubated at ambient temperature, protected from light for 30 min. After the 
incubation, 50 µL stop solution was added to each well and absorbance was 
recorded at 490 nm using the above plate reader. Percentage (%) cytotoxicity 
was determined for each experimental condition (Expt) using the formula: % 
cytotoxicity = 100 × (ODExpt – ODUntreated)/(ODMax – ODUntreated), where ODMax 
represents the absorbance of the media from a well with complete lysis of cells 
releasing maximum LDH. All assays were performed at least three independent 
times. Statistical significance was determined by a two-tailed Student’s t-test. 
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ABSTRACT 
More than 40 mutations in the gene encoding Fused in 
Sarcoma/Translocated in Liposarcoma (FUS/TLS or FUS) have been identified 
as a causal link to familial amyotrophic lateral sclerosis (fALS) – a progressive 
neurodegenerative disease characterized by loss of motor neurons. However, 
the pathogenic mechanisms by which FUS variants cause this disease remain 
largely unknown. Using recombinant GST-tagged FUS proteins we show that 
ALS mutations (R521G, R495X and G230C) induce protein misfolding compared 
to the WT protein. Interestingly, these FUS variants inhibit fast axonal transport 
(FAT) in a squid axoplasm based vesicle motility assay. The inhibitory effect was 
specific to the FUS variants as WT protein had no effect on FAT. Inhibitors of p38 
MAPK completely rescued mutant-FUS mediated FAT inhibition. Importantly, 
tissue samples from several ALS patients with FUS mutations demonstrated 
higher p38 expression and phosphorylation compared to non-ALS controls. 
These results indicate that the pathogenic mechanism of FUS variants in causing 
ALS involves the p38 MAP kinase pathway, possibly a result of structural 
perturbations induced by the disease causing mutations in FUS. 
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INTRODUCTION 
Mutations in several genes including SOD1 (Rosen et al., 1993), FUS 
(Kwiatkowski et al., 2009; Vance et al., 2009), TARDP (Gitcho et al., 2008; 
Kabashi et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van 
Deerlin et al., 2008; Yokoseki et al., 2008), PFN1 (Wu et al., 2012) and 
C9ORF72 (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2011; Renton et 
al., 2011) have been associated with familial amyotrophic lateral sclerosis (fALS), 
a progressive neurodegenerative disease that primarily affects both lower and 
upper motor neurons of brain and spinal cord. About 10% of all ALS cases are 
fALS and have a disease history within the families of patients, while the 
remaining 90% of the cases are sporadic (sALS) with no family history. Multiple 
pathogenic events affect various cellular pathways throughout the rapid course of 
the disease. Impaired axonal transport, mitochondrial dysfunction, excitotoxicity, 
oxidative stress, protein misfolding, inflammation, abnormal activation of 
proteases and kinases, have all been thought to contribute to the disease 
pathology (Pasinelli and Brown, 2006).  
Mutations in FUS account for about 5% of all fALS cases. FUS, also 
known as TLS or FUS/TLS, is an RNA/DNA binding protein that has been 
implicated in numerous cellular functions including DNA damage repair, 
transcription, RNA processing and stress response. The domain structure of FUS 
includes an N-terminal SYGQ-rich domain, a Glycine-rich region, an RNA-binding 
domain (RRM), a zinc-binding domain and the C-terminal RGG-rich domains and 
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a putative nuclear localization sequence (NLS). The C-terminal NLS harbors the 
majority of fALS causing mutations in FUS. Even though FUS, a nucleo-
cytoplasmic shuttling protein, is found predominantly in the nucleus under normal 
conditions, most of these mutations result in cytoplasmic mislocalization of the 
protein. Such a mislocalization seems to result in both loss of normal function 
and gain of toxic function for FUS. While several studies have focused on 
understanding the implications of mutant-FUS mislocalization, how these FUS 
variants exert their toxic effects is not completely understood. In particular, 
whether the mutations produce structural changes that result in protein 
misfolding is still unknown.  
Accumulation of misfolded proteins and/or their aggregates in various 
neuronal tissues has been observed in several neurodegenerative diseases. In 
fact, such an accumulation serves as the characteristic feature of several of 
these diseases. Protein misfolding can occur due to both genetic (mutations) and 
non-genetic perturbations (eg. post-translational modifications). The toxic 
confirmation resulting from protein misfolding can impair several cellular 
functions/pathways that can ultimately cause neuronal dysfunction and/or 
apoptosis (Soto and Estrada, 2008). Thus, protein misfolding has been a key 
area of investigation in ALS pathogenesis. In particular, the consequences of 
SOD1 misfolding and its role in ALS have been extensively investigated 
(reviewed in (Rotunno and Bosco, 2013)).  
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However, as mentioned earlier, whether ALS-causing mutations result in 
FUS misfolding is unclear and whether such misfolding contributes to the 
pathogenic effects of FUS is unknown. In the present study, we show that ALS-
linked FUS variants are misfolded using fluorescence anisotropy and limited 
proteolysis of recombinant proteins. We also show that misfolding has a 
functional consequence in that the FUS variants specifically inhibit fast axonal 
transport (FAT) as determined by a squid based vesicle motility assay while the 
WT FUS had no effect. The inhibition was rescued when p38 MAP kinase activity 
was blocked, indicating a role for the p38 pathway in mediating the effects of 
FUS variants. Furthermore, we show that p38 expression and phosphorylation is 
upregulated in patients with ALS. These results provide a novel insight into the 
mechanism by which FUS variants can lead to pathogenic effects in ALS. 
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RESULTS 
ALS-linked mutations induce structural perturbations in FUS  
Mutations in FUS that cause ALS result in subcellular mislocalization of 
the FUS protein, impaired transcriptional regulation and altered stress granule 
dynamics (Baron et al., 2013; Dormann and Haass, 2013).  However, whether 
these changes are a consequence of FUS misfolding is not known. In order to 
examine conformational differences between WT and FUS variants, purified 
GST-tagged FUS proteins (WT, R521G, R495X and G230C; Fig 3.1) were 
subjected to time-resolved anisotropy by measuring the excited-state decay of 
tryptophan (Trp) residues in the GST-FUS proteins. The variants used here were 
chosen so as to represent the numerous mutations within FUS in terms of their 
location and severity of disease - G230C in the Gly-rich region, R521G in the C-
terminal NLS region and the truncation mutant R495X which truncates the entire 
NLS and has a relatively severe disease phenotype (Bosco et al., 2010a; Waibel 
et al., 2012). All GST-FUS proteins have 4 Trp residues in the GST region and 3 
Trp residues in the FUS regions (Fig 3.1).  The difference in mobility (tumbling) of 
these Trp residues, serves as an indicator of the structural differences between 
those proteins. The raw intensity-decay data obtained were fit to an associative 
decay model (Fig 3.2A). The anisotropy was then determined from both the raw 
and fitted intensity-decay data for each FUS protein (Fig 3.2B). Both the 
intensity-decay data and anisotropy data correlated exactly with the fitted model. 
Overlay of the fitted anisotropy data revealed that the WT FUS had an anisotropy 
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that is different from all the three FUS variants, which had a very similar 
anisotropy to one another (Fig 3.2C). Correlation times of the FUS variants were 
determined to be very long (59.4 ns for R521G, 50.7 ns for R495X and 44.7 ns 
for G230C) indicating limited mobility of the FUS variants. However, the 
correlation time of WT was much longer (> 60ns) than that of the FUS variants, 
indicating severely limited mobility of the Trp side chain. Thus these results 
indicate that WT FUS is structurally different than the three FUS variants. 
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Figure 3.1 
Figure 3.1 Domain structure of GST-FUS protein and ALS mutations.  
Secondary structure of FUS with N-terminal GST-tag and the ALS-linked 
mutations, R521G, G230C and R495X are shown. Arrows indicate the amino 
acid position of tryptophan residues. QGSY-rich, glutamine-glycine-serine-
tyrosine-rich; G-rich, glycine-rich; RRM, RNA recognition motif; RGG, arginine-
glycine-glycine-rich; ZFD, zinc-finger domain; NLS, nuclear localization signal. 
Arrows indicate the position of tryptophan residues. 
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C) 
 
Figure 3.2 
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Figure 3.2 
Figure 3.2 Tryptophan fluorescence anisotropy of FUS proteins 
A) The intensity decay plots showing the overlay of raw data of vertical and 
horizontal components of the emitted light with their corresponding fitted data 
shows the reliability of the model. B) Similarly the raw and fitted anisotropy 
calculated from the corresponding intensity decay values shows that modeled 
data corresponds with the raw data. C) Overlay of the modeled anisotropy plots 
of WT and the three FUS variants (R521G, R495X, G230C) show that the 
anisotropy of WT is different from that of the three variants which themselves are 
similar to one another. 
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A limited proteolysis experiment was performed next to identify structural 
differences between WT and ALS-linked FUS variants.  FUS proteins (WT, 
R521G, R495X and G230C) were subjected to varying concentrations of 
chymotrypsin for 20 min at 25 °C. Enzymatically cleaved proteins were separated 
using SDS-PAGE and stained with coomassie blue to visualize the protein 
fragments. Limited proteolysis of WT exhibited a distinct cleavage pattern 
compared to the three FUS variants, all of which were identical to one another 
(Fig 3.3), indicating that WT is structurally distinct from FUS variants. In 
particular, three fragments of molecular weight (MW) between 25 and 37 kD 
appeared equally prominent among the FUS variants (Figure 3.3) while only one 
fragment appeared in the WT in that MW range. Furthermore, peptides between 
37 and 50 kD that were present for the FUS variants (Figure 3.3) were absent in 
the WT. Although a loss of arginine in R521G and R495X could affect the way 
peptides get separated on SDS-PAGE, due to the charge differences, a similar 
peptide pattern was observed with G230C, indicating that the loss of arginine 
does not have an effect on the SDS-PAGE of the peptides. Overall, these results 
are consistent with a misfolded conformation for ALS-linked FUS proteins.   
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Figure 3.3 
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Figure 3.3 Structural differences between WT and ALS-linked FUS proteins 
FUS proteins (WT, R521G, R495X and G230C) were digested with increasing 
concentrations of chymotrypsin (0, 1:250000, 1:25000, 1:1250, 1:833, 1:500 
(w/w) enzyme to protein) for 20 min at 25 °C and the peptides were separated by 
SDS-PAGE. Representative gels (n=3) stained with coomassie blue revealed 
that the cleavage pattern of WT was distinct from the three FUS variants, all of 
which exhibited the same pattern. Peptides denoted by # are present in the FUS 
variants but not in the WT protein while peptides within the region denoted by * 
has three prominent bands for FUS variants and only one prominent band for the 
WT.  
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The limited proteolysis experiments show that fragments between 25 and 
37 kD, preferentially accumulate in the FUS variants as chymotrypsin 
concentration is increased. When FUS proteins (WT and R521G) were digested 
with a fixed concentration of chymotrypsin (1:500 (w/w) enzyme to protein) over a 
time course (0, 10, 20 min, 2 or 24 h), the cleavage pattern looked similar 
between WT and mutant-FUS by 24 h (Fig 3.4). However mutant-FUS required 
longer incubation time to obtain cleavage similar to WT, as the pattern was 
different between these proteins for at least the first 2 h of the experiment. These 
results indicate that mutant FUS structure is better protected from enzymatic 
digestion compared to WT FUS and requires longer incubation with chymotrypsin 
to be digested to a similar extent as WT FUS. 
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Figure 3.4 
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Figure 3.4 Mutant-FUS proteins require longer chymotrypsin incubation for 
complete digestion 
FUS proteins (WT and R521G) were digested with chymotrypsin (1:500 (w/w) 
enzyme to protein) for 0, 10, 20 min, 2 or 24 h and the peptides were separated 
by SDS PAGE. Representative gels (n=2) stained with coomassie blue revealed 
that the cleavage pattern of WT FUS was distinct than that of the mutant-FUS 
protein at least until 2 h.  By 24 h, both the patterns were indistinguishable. 
These results indicate that mutant-FUS requires longer incubation with 
chymotrypsin to be digested to a similar degree as WT FUS.  
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Limited proteolysis experiments show that despite differences in the 
sequence location of FUS mutations (G230C in the glycine-rich region, R521G in 
the C-terminal NLS region, and the truncation mutation R495X which completely 
eliminates the NLS) they all result in misfolding of FUS. The resistance of FUS 
mutants to chymotrypsin cleavage, indicated by the presence of higher number 
of peptides, suggests that the mutants are protected better from chymotrypsin 
digestion than WT. In order to identify the regions that are variably protected 
between WT and FUS variants, the fragments obtained after digestion with 
chymotrypsin were probed with an antibody against GST (Ab1) and several 
antibodies against different regions of FUS (Ab2-7; Fig 3.5A) by western blot. All 
the antibodies recognized the four undigested FUS proteins. Interestingly, the 
GST antibody (Ab1) and Ab2 (against residues 1-50 at N-terminal of FUS) 
identified several peptides in the FUS variants but only one major peptide in WT 
(Fig 3.5B). That these antibodies recognize GST and the N-terminal region of 
FUS suggests that the N-terminal region of FUS variants is protected from 
proteolysis by chymotrypsin. On the other hand, none of the other antibodies 
showed any major differences in the digestion pattern between the FUS proteins 
(Fig 3.5C). These results indicate that there are minimal to no structural 
differences in other regions of the proteins or that the conditions used here 
(enzyme, concentration, time of digestion) only captures differences in the N-
terminal region. 
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Figure 3.5 
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Figure 3.5 
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Figure 3.5 Antibody mapping of enzymatically digested FUS peptides 
A) The epitopes for the indicated anti-GST and FUS antibodies used in this study 
are mapped onto the domain structure of GST-FUS. B) FUS proteins were either 
undigested or digested with chymotrypsin for 20 min at 25 °C and western blot 
analyses were performed using the antibodies indicated in (A). Intact FUS 
proteins were detected by all antibodies tested. B) Both GST (Ab1) and FUS 
(Ab2) antibodies revealed differences in digestion pattern between WT and FUS 
variants. C) None of the other antibodies (Ab3-7) showed any major differences 
between WT and FUS variants. 
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In order to identify the specific N-terminal region that is better protected in 
FUS variants,  the bands between 25 and 37 kD (three for R521G and 1 for WT, 
see Fig 3.3) were excised from the gel and subjected to mass spectrometry 
analysis (Fig. 3.6A). To determine the abundance of each peptide, extraction ion 
chromatogram (EIC) was generated first for each peptide identified in both WT 
and R521G samples from two independent experiments (Fig. 3.6B). The peak 
area for the peptides was determined from the EICs and the ratio of WT/R521G 
was calculated as an average for the two independent experiments (Table 3.1). 
An increase or decrease by 50% or more (WT/R521G<=0.5 or >=1.5) indicated a 
change in peptide abundance while the rest of the peptides were considered as 
unchanged. The WT/R521G ratio revealed several peptides within the QGSY-
rich region of FUS that are more abundant in the mutant (WT/R521G <= 0.5; 
Table 3.1 and Fig. 3.6C, shown in blue). Furthermore, the peptides identified in 
this region were all higher in R521G strengthening the confidence of the result 
suggesting that this region is better protected in mutant-FUS. While a majority of 
peptides remained unchanged (0.5<WT/R521G<1.5; Table 3.1 and Fig. 3.6C, 
shown in gray) a few peptides were higher in WT (WT/R521G ratio>1.5; Table 
3.1 and Fig. 3.6C, shown in red) in the GST region and RRM/RGG1 region of 
FUS. The lesser protection of N-terminal region of WT FUS explains the higher 
abundance of peptides in GST region for WT FUS.  The RRM/RGG1 region 
peptides abundant in the WT-FUS indicate that this region could be better 
protected, although the relatively small number of peptides indentified does not 
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provide the confidence to support such protection. Analysis of all the peptides 
obtained after chymotrypsin digestion, could provide better insight on those 
regions of FUS. Combining the peptides that were significantly higher in the 
mutant-FUS revealed a 41-amino acid region (residues G15 to Y55 in FUS) that 
is better protected in R521G than in WT from chymotrypsin digestion (Fig 3.6D). 
These results indicate that the mutations in FUS cause the N-terminal region of 
FUS to be better protected from chymotrypsin digestion.  
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Figure 3.6 
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Figure 3.6 N-terminal region of FUS variants is better protected from limited 
proteolysis  
FUS proteins (WT and R521G) were subjected to limited proteolysis by 
chymotrypsin. The digested peptides were separated using SDS-PAGE and 
stained with coomassie blue to visualize the peptides. A) Boxed regions were in-
gel digested with chymotrypsin, extracted from the gel and subjected to mass 
spectrometry analysis. B) Extraction ion chromatograms (EIC) of peptides in WT 
(first panel) and R521G (second panel) used were generated as shown. Peptide 
abundance was determined by calculating the peak area from the EIC and 
normalizing to the total intensity of the sample. Subsequently the ratio of each 
peptide in the WT and R521G sample (WT/R521G) was determined. C) The 
average of the ratios from n=2 experiments were calculated and peptides with 
ratio <0.5 (more abundant in R521G) are shown in blue, peptides with ratio >1.5 
(more abundant in WT) are shown in red and peptides with ratios 0.5-1.5 
(unchanged between WT and R521G) are shown in gray. D) The analysis 
revealed that a 41 amino acid region (G15 to Y55, highlighted in green) in 
QGSY-rich domain of FUS is better protected in R521G than in WT.  
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Table 3.1 
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Table 3.1 Quantification of peptides in WT and R521G FUS samples 
Relative abundance of identified peptides were calculated from the peak area of 
the EIC (n=2). The peak area was used to determine the ratio of peptide levels in 
WT FUS compared to R521G (standard deviation, Std Dev; standard error, SEM) 
Peptides increased in WT by more than 50% (WT/R521G ratio >1.5) are 
indicated in red, while peptides decreased in WT by more than 50% (WT/R521G 
ratio <0.5) are shown in blue. Unchanged peptides (WT/R521G ratio 0.5<1.5) are 
shown in gray. 
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FUS variants inhibit anterograde and retrograde fast axonal transport  
Limited proteolysis studies demonstrate that ALS-linked FUS variants 
G230C, R521G and R495X are all misfolded. In order to investigate the 
functional consequence of protein misfolding, we used a squid axoplasm based 
assay to monitor the effect of FUS proteins on vesicular motility (Brady et al., 
1993). The squid assay has been used successfully to demonstrate the toxicity of 
several other proteins involved in neurodegenerative diseases, such as 
misfolded WT and mutant-SOD1 (Bosco et al., 2010b; Morfini et al., 2013; Song 
et al., 2013), both of which demonstrated an inhibitory effect on fast axonal 
transport.  FUS proteins were perfused into a membrane free axoplasm 
preparation.  Video-enhanced microscopy was used to monitor the velocities of 
membrane bound organelles, allowing us to quantify fast axonal transport (FAT) 
in both anterograde and retrograde directions. Perfusion of 2.5 µM WT FUS 
protein had no effect on FAT in either direction for the duration of the assay (50 
min; Fig 3.7A). Strikingly, perfusion of 2.5 µM of R521G, R495X or G230C FUS 
resulted in inhibition of FAT in both directions (Figs 3.7B, C and D), 
demonstrating a mutant-specific phenotype for FUS proteins.  
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Figure 3.7 
 
 107 
 
Figure 3.7 ALS-linked FUS proteins inhibit axonal transport 
FUS proteins were perfused onto extruded squid axoplasm and vesicular 
transport (velocity μm/s), representing fast axonal transport (FAT), was plotted 
against time (minutes). Blue arrows and line represent anterograde velocities 
while red arrows and line represent retrograde velocities. Perfusion of WT FUS 
(A) had no effect on transport in either direction while perfusion of FUS mutants 
R521G (B), R495X (C) or G230C (D) inhibited FAT in both anterograde and 
retrograde directions. 
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FAT inhibition by mutant-FUS is mediated by p38 MAPK  
Specific protein kinases have usually been found to mediate axonal 
transport inhibition by several misfolded and toxic proteins (Morfini et al., 2009).  
In the case of ALS causing SOD1 proteins, which inhibit axonal transport only in 
the anterograde direction, p38 MAP kinase mediates FAT inhibition (Morfini et 
al., 2013).  In order to determine if p38 MAP kinase played a similar role in FUS 
mediated FAT inhibition, FUS R521G was co-perfused with inhibitors of p38 
MAPK, SB203580 or MW-069 (Munoz et al., 2007). p38 inhibition rescued the 
FAT inhibition completely (Fig 3.8A and B). In contrast, co-perfusion of JNK 
kinase inhibitor SP600125 did not rescue the FAT inhibition by FUS R521G (Fig 
3.8C). These results indicate that mutant-FUS mediated FAT inhibition is 
regulated by p38 MAP kinase specifically. Furthermore, even though mutant-
SOD1 and mutant-FUS have distinct effects on FAT, i.e., ALS causing SOD1 
only inhibits anterograde transport whereas ALS FUS inhibits both anterograde 
and retrograde axonal transport, they are at least in part regulated by the same 
MAPK pathway. Interestingly the different isoforms of p38 MAPK have different 
effects on FAT as the alpha isoform has been shown to inhibit anterograde 
transport while the beta isoform inhibits anterograde and retrograde transport 
(Morfini et al., 2013). Thus in the case of mutant-FUS, where both directions are 
affected, the inhibition is presumably mediated by p38β alone or through a 
combination of both p38α and β isoforms. 
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Figure 3.8 
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Figure 3.8 p38 MAPK mediates FAT inhibition by mutant-FUS 
Co-perfusion of either of the p38 MAPK inhibitors, SB203850 (A) or MW069 (B), 
rescued FUS R521G-induced inhibition of FAT (Fig. 3.8) indicating a role for p38 
activation in mediating the inhibitory effect on FAT. Co-perfusion of the JNK 
inhibitor SP600125 (C) did not rescue the FAT inhibition by mutant-FUS, 
indicating a specific role for p38 MAPK.  
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In order to determine if FUS variants exert their inhibitory effect on FAT by 
p38 MAPK alone or if upstream kinases are involved, FUS R521G was co-
perfused with an inhibitor (NQDI-1) against ASK1, an upstream MAP kinase of 
p38 MAPK. Monitoring the axonal transport revealed that retrograde transport 
was rescued completely and anterograde transport was partially rescued 
indicating a role for the upstream factors in the MAPK cascade in mediating the 
inhibitory effect on FAT (Fig 3.9A, C). These results are in agreement with a 
recent study showing that MST1 mediates the activation of p38 MAPK by ALS 
linked mutant-SOD1 (G93A), supporting the notion that the MAP kinase cascade 
itself might be involved (Lee et al., 2013). Furthermore, one study showed that 
HSP110, a nucleotide exchange factor for HSP70, rescued the inhibitory effect of 
ALS-linked mutant-SOD1 protein G85R, presumably by mitigating the toxic 
effects of protein misfolding (Song et al., 2013). Since the ALS linked FUS 
proteins used in this study are misfolded (Figs. 3.2-3.6), we tested if protein 
misfolding is involved in exerting toxic effects on axonal transport. To that end, 
FUS R521G was co-perfused with recombinant HSP110 and axonal transport 
was monitored as above (Fig 3.9B). HSP110 was able to rescue axonal transport 
in both directions to levels comparable to that of WT FUS (Fig. 3.7A), indicating a 
role for protein misfolding in exerting toxic effects on axonal transport. 
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Figure 3.9 
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Figure 3.9 Aberrant kinase activation caused by protein misfolding inhibits 
axonal transport 
A) Co-perfusion of NQD1, an inhibitor of ASK1 which is upstream of p38 MAPK, 
with FUS R521G partially rescued FAT inhibition, indicating a role for the MAPK 
cascade in mediating inhibitory effect on axonal transport. B) Co-perfusion of 
HSP110 also rescued the inhibitory effect of mutant-FUS supporting that protein 
misfolding results in aberrant activation of the MAPK cascade thereby affecting 
axonal transport. C) Model of aberrant kinase activation caused by protein 
misfolding. Misfolded FUS proteins result in the activation of the p38 MAPK 
cascade that involves ASK1 as the upstream MAPKKK. Activated p38 MAPK 
inhibits axonal transport by targeting and impairing molecular inhibitors such as 
kinesin and dynein. Correction of protein misfolding by molecular chaperones 
such as Hsp110 or inhibition of kinase activity by small molecule inhibitors 
(NQDI-1 for ASK1 and SB203580 or MWO69 for p38) rescues the axonal 
transport inhibition mediated by misfolded FUS. 
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P38 MAPK expression and phosphorylation is increased in fALS patients 
with FUS mutations  
Activation of p38 MAPK has been implicated in several neurodegenerative 
diseases including ALS (Bendotti et al., 2005; Correa and Eales, 2012). 
Increased p38 MAPK immunoreactivity has been reported in sporadic ALS cases 
and a familial ALS patient with SOD1 mutation H48Q (Ackerley et al., 2004; 
Bendotti et al., 2004). However, there is no evidence of p38 MAPK activation in 
fALS patients with FUS mutations. In order to investigate the changes in 
expression and activation of p38 MAPK, tissue samples obtained from control 
and fALS-FUS patients were analyzed by western blot for total p38 as well as 
phosphorylated p38 indicative of activated kinase. Interestingly both the total and 
phosphorylated forms of p38 were increased in several fALS patients compared 
to the mean of the control population in both brain and spinal cord tissues (Fig 
3.10). However statistical significance was not achieved between the control and 
ALS groups, which could be due to small sample size owing to the rareness of 
the disease and inconsistencies in tissue collection and storage procedures. 
Nonetheless, these results not only further support that aberrant activation of p38 
MAPK could be a component of ALS disease pathology, but also lays 
precedence for the involvement of aberrant processing of p38 MAPK that results 
in  altered expression. Whether this aberrant processing is a consequence of 
mutations in FUS is being currently explored in our lab. In particular the role of 
mircoRNAs in mediating the pathogenic effects of FUS variants is being 
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investigated. One microRNA of interest is miR-124, which is downregulated in 
injured motor neurons (Nagata et al., 2014) as well as in cells when FUS levels 
are reduced (Morlando et al., 2012). Interestingly miR-124, along with miR-128, 
suppresses the expression of p38α in neurons (Lawson et al., 2013). Thus, we 
are investigating whether or not misregulation of miR-124 by mutant-FUS could 
alter the expression of p38 MAPK.  
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Figure 3.10 
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Figure 3.10 Activation of p38 MAPK in ALS patients  
Post-mortem tissue samples of control (C1-11) and FUS-fALS patients (S1-6 & 
B1-6) were prepared for western blot analysis and probed for total and phospho-
p38 (indicative of activated p38) levels. Western analysis revealed that in both 
brain (A, B) and spinal cord (C, D) tissue samples of FUS-fALS patients, total 
and phospho-p38 levels, indicative of activated p38 MAPK, were higher in 
several of the ALS cases relative to the mean of the control group. 
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DISCUSSION 
FUS is a multifunctional protein that is associated with several types of 
cancers and the neurodegenerative diseases, ALS and FTLD (Frontotemporal 
lobar degeneration). Ever since the association with ALS was discovered, there 
has been an increased attention for both understanding the disease mechanisms 
and normal functions of FUS. While significant progress has been made in 
understanding the normal functions of FUS, resulting in the emergence of novel 
functional roles in DNA damage repair and stress response, the knowledge on 
how mutations in FUS can lead to ALS is still very limited. FUS is a DNA/RNA 
binding protein that shuttles between the nucleus and cytoplasm but is found 
mostly in the nucleus under normal conditions (Zinszner et al., 1997). A majority 
of ALS-linked mutations have been found in the C-terminal nuclear localization 
signal (NLS) and thereby result in mislocalization of the FUS variants. While a 
few mutations also span the central Glycine rich regions, these mutations have 
been rarely examined. One recent study however showed that even these 
mutations are pathogenic in the context of DNA damage repair (Wang et al., 
2013).  
Thus in order to understand not only the pathogenic effects of FUS 
mutations in general but also to understand the differences across various FUS 
mutations, we have used three FUS variants for our studies – G230C in the Gly-
rich region, R521G in the C-terminal NLS region and the truncation mutant 
R495X, which truncates the entire NLS. Despite the differences in domain 
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location of these three variants, they showed a similar digestion pattern with 
chymotrypsin indicating that these pathogenic mutations affect the protein 
structure in a similar way (Fig 3.3). Interestingly, mass spectrometry and antibody 
mapping experiments revealed that regardless of where the mutation is located 
within the protein, structural perturbations occurred in the N-terminal QGSY-rich 
region of FUS (Figs 3.5 and 3.6). This is very interesting in that previous studies 
reported mutations in the NLS significantly perturbed transportin binding, which 
affected the nuclear import of these proteins and results in cytoplasmic 
mislocalization (Dormann et al., 2012; Niu et al., 2012; Zhang and Chook, 2012). 
Our results however, indicate that structural differences also persist in the N-
terminal region of FUS, which potentially mediates the pathogenic effects of the 
proteins. Interestingly a prion-like domain has been identified in the N-terminal 
region of FUS that is thought to promote aggregation of FUS (Gitler and Shorter, 
2011; Sun et al., 2011). Thus despite being unclear as to how mutations in 
different regions result in perturbing the prion-like domain of FUS, these 
structural perturbations appear to inflict pathogenic properties to the FUS 
variants as demonstrated by axonal transport assays (Fig 3.7 and 3.8).  
A recent study using recombinant FUS proteins showed that WT FUS 
protein was extremely aggregation prone and mutations did not enhance 
aggregation propensity of the FUS protein (Sun et al., 2011). Thus the proteins 
could exert their pathogenic effects by other means. In our current study we 
investigated the pathogenic effect of FUS variants on axonal transport. For this 
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purpose we used a squid axoplasm based vesicle motility assay. The assay has 
been previously used to demonstrate the toxic effects of several 
neurodegenerative disease-causing proteins as well as identifying the pathogenic 
mechanisms (Morfini et al., 2009). We have shown here that FUS variants all 
inhibit fast axonal transport (Fig 3.7). This is one of the few instances where a 
mutant-specific phenotype has been observed in contrast to most cases where 
WT FUS also exerted pathogenic effects.  
Interestingly, a recent study demonstrated that the ALS-linked TDP43 
impaired axonal transport of mRNP particles (Alami et al., 2014). Thus it is 
possible that axonal transport impairment, which appears to be central to axonal 
degeneration and can ultimately lead to the death of the neuron (Fischer-Hayes 
et al., 2013), plays a major role in ALS pathogenesis as suggested previously 
(Pasinelli and Brown, 2006).  
For several years, SOD1 has been the only known cause of fALS and 
hence most of our understanding about the pathways affected in ALS has been 
deduced from studies of SOD1. However, with the discovery of proteins such as 
FUS and TDP43, there has been an interest in determining the 
common/converging pathways that are part of the disease pathogenesis. For 
instance, functions related to RNA processing are thought play a role in disease 
pathogenesis given the role of both FUS and TDP43 in various aspects of RNA 
processing. We show here that ALS-linked FUS variants inhibit axonal transport, 
supporting impaired axonal transport as a common pathway in ALS as suggested 
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by the similar effects produced by ALS-linked SOD1 (Bosco et al., 2010b; Morfini 
et al., 2013) and TDP43 (Alami et al., 2014). Furthermore, we also show here 
that ALS-causing FUS proteins inhibit axonal transport in both anterograde and 
retrograde directions (Fig 3.7). As mentioned earlier such inhibition is potentially 
mediated by either p38β isoform alone or both p38 α and β isoforms, unlike for 
SOD1 whose pathogenic effects are mediated by p38α isoform in inhibiting 
anterograde axonal transport. Thus despite the pathogenic effects of ALS 
causing proteins are affecting the same pathways, the mechanism might be 
different.  
Finally we investigated the brain and spinal cord tissue samples of ALS 
patients for both p38 levels and activation (Fig 3.10). As expected, an increase in 
phosphorylated p38 levels was observed in several patient samples. Surprisingly, 
even the total p38 levels were higher in many patient samples. Given the role of 
FUS in transcriptional regulation, it is possible that FUS can also regulate the 
expression of several genes, such as p38 in this case. These results indicate the 
involvement of aberrant kinase regulation in ALS disease pathology. 
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MATERIALS AND METHODS 
Recombinant FUS expression and purification 
FUS WT, R521G, R495X or G230C constructs cloned into pGEX-6P1 
vector (GE Life Sciences) were transformed into Rosetta DE3 cells (Novagen). 
The cells were streaked onto LB (Luria broth)-agar plates containing 50 µg/mL 
ampicillin and incubated overnight at 37 °C. Single colonies were inoculated into 
5 mL LB medium containing 100 µg/mL ampicillin (amp) and 34 µg/mL 
chloramphenicol (cam) and incubated on a shaker at 37 °C for 8 hours. The 
starter cultures were then inoculated into 150 mL (intermediate culture) LB media 
(containing amp and cam) and incubated at 30 °C for ~24 hours. The 
intermediate cultures were then inoculated into 2 liter LB medium (containing 
amp and cam) such that the OD600 of the culture is between 0.1-0.2. The large 
cultures were then incubated on a shaker at 20 °C until the OD600 reaches ~0.8. 
FUS expression was induced by addition of IPTG (Isopropyl β-D-1-
thiogalactopyranoside) to a final concentration of 150 µM. Zncl2 was also added 
to a final concentration of 50 µM, and the cultures were incubated on the shaker 
for 22 hours at 20 °C. The cultures were centrifuged and the cell pellets were 
resuspended in lysis buffer – 50 mM Tris pH 8.0 with 1 mM DTT (Dithiothreitol), 
0.1 mM EDTA (Ethylenediaminetetraacetic acid) and protease inhibitor cocktail 
(Roche). 10 µg/mL of RNase A was added to the resuspended cells, and the 
cells were lysed by sonicating on ice at the following amplitudes and for the 
indicated durations making sure the lysate does not become warm by incubating 
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it on ice between each sonication step – 10% for 15 s; twice at 20% for 15 s; 
twice at 30% for 15 s; 35% for 15 s and thrice at 40% for 12 s. The lysate was 
spun down twice at 13000 rpm for 20 min at 4 °C in a refrigerated centrifuge and 
the supernatant was incubated with Glutathione-Agarose (Sigma, #G4510) resin 
that was pre-washed several times with 50 mM Tris buffer pH 8.0 on an end-
over-end rocker at 4 °C for 2 hours. The unbound lysate was removed by 
centrifuging the lysate/resin at 4000 rpm for 5 min at 4 °C. The resin was then 
transferred into a 5 mL polypropylene column (Pierce, #29922) and the GST-
FUS protein bound to the resin was eluted with elution buffer – 50 mM Tris pH 
9.5 with 10 mM L-Glutathione reduced (Sigma, #G4251) and 1 mM DTT. The 
collected protein was concentrated and buffer-exchanged into 25 mM Hepes 
buffer containing 1 mM DTT. The protein was aliquoted and stored at -80 °C until 
further use. 
Time-resolved anisotropy 
Time-resolved anisotropy was obtained from the excited-state decay of 
Trp residues recorded using time-correlated single photon counting (TCSPC) 
(Wu et al., 2008; Arai et al., 2011). The TCSPC system utilized an SPC-150 
(Becker and Hickl, Berlin, Germany) and fast photomultiplier tube.  The excitation 
was provided by the 292 nm tripled output of a Ti:sapphire laser at 3.8 MHz 
repetition rate (Coherent, Palo Alto, CA).  Excitation power was kept at several 
hundred μWatts.  A single L-format arrangement was used with a motorized 
Glan-Taylor polarizer.  The polarization alternated between vertical and 
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horizontal polarization and ~20x30 s acquisitions were collected and summed for 
each polarization per sample.  Counting rates were limited to ~5x105 counts per 
second.  A 357 nm 40 nm wide bandpass filter (Semrock, Rochester, NY) was 
used to select the Trp emission.  Excitation was vertically polarized.  The G-
factor was obtained from the integrated intensity of N-acetyl-tryptophanamide 
(NATA) with the data prior to 1 ns after the pulse arrival excluded to insure 
complete depolarization of NATA.  The instrument response was obtained by 
detecting scattered light with a 292 nm filter. 
  A home-built autosampler running custom LabVIEW software (available at 
www.osmanbilsel.net) was used for all time-resolved anisotropy measurements.  
Approximately 500 µL of each sample in a 96-well microplate was brought into a 
flow cell (1mm x 1mm) using a computer controlled syringe pump and flowed in 
an oscillating pattern at a flow rate of10 µL/s during data collection.  This reduced 
continuous exposure of the sample to the beam to <1 s and minimized 
photobleaching.  All samples were run in triplicate. 
The TCSPC anisotropy data were fit to an associative decay model as 
described previously (Bilsel et al., 1999).  Briefly, the horizontal and vertical 
excited state decays are described by the following expressions: 
where n is the number of  molecular species, 
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The total intensity is obtained in the usual manner, S(t)=Ivv(t)+2GIvh(t), where 
G=Ihv/Ihh (Lakowicz, 2006). In the above expressions Si(t) and ri(t) are the 
fluorescence intensity and anisotropy, respectively, for species i.  The 
fluorescence lifetime and rotational correlation time are represented by  and , 
respectively.  Thus, the total fluorescence for species i is represented by m 
exponential terms and the anisotropy decay is represented by p rotational 
correlation times.  In this manner one obtains j, j, k and k.  All non-linear 
least-squares analysis utilized the Marquardt-Levenberg algorithm using the 
package Savuka (Bilsel et al., 1999). 
Limited Proteolysis 
FUS proteins were incubated with the indicated amounts of chymotrypsin 
(Promega, #V1062) for 20 min at 25 ºC. The enzymes were inactivated by adding 
6X SDS sample buffer (Boston Bioproducts, BP-111R) and boiling the samples 
for 10 min. The samples were cooled down to room temperature and were used 
for western blot, gel staining or mass spectrometry analysis.  
Western Blot 
Western blots were performed as described (Bosco et al., 2010a). Briefly, 
samples were separated using SDS-PAGE and transferred onto a nitrocellulose 
membrane. The blots were incubated in blocking buffer (Li-cor, #927-40000) for 1 
 126 
 
h followed by overnight incubation with shaking at 4 °C in the presence of the 
following primary antibodies at a dilution of 1:1000-1:2000: anti-GST (GE 
Healthcare, #27-4577-01),  anti-FUS (Bethyl Laboratories, #A300-302A, #A300-
292A, #A300-293A), anti-FUS (in house antibody created against 264-284 
peptide sequence of human FUS, Genscript), anti-FUS (Santacruz 
Biotechnology, #47711, #373888), anti-phospho-p38 (Cell Signaling, #9215), 
anti-total-p38 (Sigma, #M0800) and anti-gapdh (Sigma, #G8795). Densitometry 
was performed using the Odyssey infrared imaging systems software (Li-cor).  
Gel staining 
Samples were separated using SDS-PAGE and the gels were stained with 
coomassie brilliant blue G250 (Sigma, #27815) or silver stain (Bio-rad, #161-
0449) to visualize the protein samples. In the case of coomassie, the gels were 
incubated in the presence of coomassie solution (0.25% (w/v) coomassie brilliant 
blue, 40% (v/v) methanol and 10% (v/v) acetic acid) for 30 min on a shaker and 
then transferred to the destaining solution until the protein/peptide bands become 
visible while replacing the destaining solution with fresh solution occasionally.  
Identification of FUS sequence by mass spectrometry 
Following limited proteolysis, SDS-PAGE, and Coomassie stain 
(described above), the indicated bands were excised from the gel and subjected 
to in-gel digestion with chymotrypsin (10 ng/ l) for 18 h at 25 C, as previously 
described (Shevchenko et al., 2006). The extracted peptides (50 µL volume) 
were dried down in a speedvac, resuspended in 12 l of 5% acetonitrile 
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containing 0.1% (v/v) trifluoroacetic acid and separated on a NanoAcquity 
(Waters) UPLC.  The run conditions follow the “sensitive” conditions 
recommended by (Kelstrup et al., 2012) for optimizing the operations of the Q 
Exactive for low abundance proteins. Briefly, a 4.5 µL injection was loaded in 5% 
acetonitrile containing 0.1% formic acid at 4.0 µL/min for 4.0 min onto a 100 µm 
I.D. fused-silica pre-column packed with 2 cm of 5 µm (200Å) Magic C18AQ and 
eluted using a gradient at 300 nL/min onto a 75 µm I.D. analytical column packed 
with 25 cm of 3 µm (100Å) Magic C18AQ particles to a gravity-pulled tip. The 
solvents were A, water (0.1% formic acid); and B, acetonitrile (0.1% formic acid). 
A linear gradient was developed from 5% solvent A to 35% solvent B in 60 
minutes. Ions were introduced by positive electrospray ionization via liquid 
junction into a Q Exactive hybrid mass spectrometer (Thermo). Mass spectra 
were acquired over m/z 300-1750 at 70,000 resolution (m/z 200) and data-
dependent acquisition selected the top 12 most abundant precursor ions for 
tandem mass spectrometry by HCD fragmentation using an isolation width of 1.2 
Da, and collision energy of 25, and a resolution of 35,000.  The raw data was 
searched against a database containing the GST-FUS sequence in Proteome 
Discoverer 1.3 with parent tolerance of 10 ppm and fragment ion tolerance of 
0.05 Da. Peak areas from extracted ion chromatograms (Skyline) were used to 
quantify the abundance of the peptides in each sample. The individual peak 
areas were normalized to the sum of all peak areas identified as FUS peptides. 
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Peptides in GST-FUS WT were further normalized to the corresponding peptide 
in GST-FUS R521G. Only changes of >50% were included in the analyses. 
Squid axoplasm vesicle motility assays 
Vesicular motility assays were performed as described previously (Morfini 
et al., 2013). FUS proteins alone or in combination with pharmacological 
inhibitors or HSP110 protein were diluted into X/2 buffer (175 mM potassium 
aspartate, 65 mM taurine, 35 mM betaine, 25 mM glycine, 10 mM Hepes, 6.5 mM 
MgCl2, 5 mM EGTA, 1.5 mM CaCl2, 0.5 mM glucose, pH 7.2) supplemented with 
2–5 mM ATP, and 25 µL were perfused into the membrane-free axoplasms. The 
final concentrations are as follows:  2.5 µM of FUS proteins, 5 µM of SB203580, 
0.5 µM of SP600125, 10 µM of MW-069, 20 µM NQDI1 and 0.6 µM HSP110. 
Vesicular transport rates in both anterograde and retrograde directions were 
obtained and plotted using Prism (GraphPad software). 
 
 
Human Tissue analysis 
Human post-mortem tissues were obtained from ALS patients and control 
individuals after obtaining informed consent. The tissues were frozen until further 
analysis. All protocols were approved by Institutional Review Board by all the 
institutions involved. For western analysis, tissue samples were transferred to 2 
mL borosilicate glass tube (Wheaton, #358028) and lysis buffer was added. The 
samples were homogenized using a tissue grinder (Wheaton, #358029) 
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connected to an overhead stirrer (Wheaton, #903475) homogenizer by stirring for 
3 min at setting 2 and 4˚C. The lysate was transferred to centrifuge tubes and 
was centrifuged using a table top refrigerated centrifuge for 15 min at 13000 rpm 
and 4˚C. The supernatant was transferred to fresh tubes and centrifuged again 
for 15 min at 13000rpm and 4˚C. The supernatants were collected and protein 
concentration was determined using a colorimetric assay based on bicinchonic 
acid (BCA) (ThermoScientific, #23227 ) for western analysis. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
Amyotrophic lateral sclerosis is a deadly neurodegenerative disease that 
affects nearly 5,000 individuals every year in the USA. The debilitating nature of 
this disease severely affects the individuals and their families. Despite being 
known for over one hundred years now, only one FDA approved treatment exists, 
Riluzole, which only extends life by a few months.  The encouraging news, 
however, is that there has been a significant development in our understanding 
of ALS owing to research findings over the last few years, bringing us closer than 
ever to finding a treatment and/or cure. Particularly, genetics have helped us 
identify several genes linked to the disease. This in turn has helped us 
understand the molecular mechanisms behind the pathogenesis of ALS. 
FUS/TLS or FUS is a key gene in which mutations causing ALS have been 
discovered. Mutations in FUS account for nearly 5% of all familial ALS cases. 
Understanding the normal functions of FUS and its pathogenic role in causing 
ALS has recently gained considerable attention in the ALS field. Chapter II of this 
dissertation deals with a novel prosurvival function for FUS under hyperosmolar 
stress conditions. Additionally, in chapter III we explored how ALS causing 
mutations can induce structural perturbations in FUS and lead to protein 
misfolding and aberrant kinase activation. Thus the work presented in this 
dissertation is aimed at advancing our understanding of potential pathogenic 
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mechanisms of this deadly disease and to hopefully obtain some clues as to how 
to find a treatment and/or even a cure. 
FUS is a multifunctional protein that is involved in several key cellular 
functions such as DNA damage repair, transcriptional regulation, RNA 
processing and stress response (Dormann and Haass, 2013; Ling et al., 2013). It 
is still unclear if a loss of one or more of these functions or if gain-of-toxic 
function(s) by FUS variants leads to ALS.  Interestingly the cellular functions 
investigated usually seem to dictate the type of mechanism. For instance, despite 
some conflicting results, ALS-linked FUS variants appear to be defective in DNA 
damage repair supporting a loss of function mechanism (Mastrocola et al., 2013; 
Rulten et al., 2013; Wang et al., 2013). On the other hand, one study 
investigating the mRNA targets bound by WT and mutant-FUS, show that 
mislocalization of FUS resulted in the mutant-FUS binding several hundreds of 
novel mRNAs, supporting a gain of toxic function hypothesis (Hoell et al., 2011). 
The key focus of the work presented in this dissertation is the role of FUS in 
stress response. Previous studies showed that FUS variants that are 
mislocalized to the cytoplasm incorporate into stress granules (Bosco et al., 
2010a; Dormann et al., 2010; Gal et al., 2011; Kino et al., 2011; Bentmann et al., 
2012) and alter several properties of stress granules, supporting a gain of 
function hypothesis (Baron et al., 2013). However, a majority of studies that 
looked at the role of FUS in stress granules were limited by the type of stress 
conditions used and thus did not reveal a role for endogenous FUS under such 
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conditions. The work presented in Chapter II of this dissertation demonstrates 
that WT endogenous FUS not only responds to hyperosmolar stress, but also 
plays a pro-survival role under such conditions. The response of FUS involves 
immediate translocation to the cytoplasm and incorporation into stress granules. 
But how does mutant-FUS respond to hyperosmolar stress? Our work using an 
artificial truncation mutation, G515X that eliminates the NLS showed that the 
mutant protein still incorporates into stress granules (Fig 2.9). Whether ALS-
causing FUS variants also incorporate into stress granules has not been 
investigated. Evaluating whether the FUS variants still play a pro-survival role 
under hyperosmolar conditions and disassociate from stress granules in the 
same manner as WT FUS would be key in determining whether this function of 
FUS is linked to the pathogenesis of ALS. Also interesting would be to 
investigate if the cytoplasmic translocation of FUS proteins also causes a loss of 
nuclear functions, which could be exacerbated with variants that are already 
mislocalized to cytoplasm.  
Stress granules are formed in response to transient stress and 
disassemble upon removal of the applied stress. However, under chronic stress 
conditions, stress granules have been suggested to act as precursors to end-
stage aggregates that are usually detected in neurons of ALS patients (Wolozin, 
2012). Supporting this notion, several stress granule marker proteins were 
detected in inclusions of ALS and FTD patients (Dormann et al., 2010; Liu-
Yesucevitz et al., 2010; Bentmann et al., 2013). Interestingly, expression of ALS-
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causing FUS variants in cultured cells resulted in varying degrees of FUS 
mislocalization alone without any toxicity. However, upon stressing the cells with 
oxidative stress, ER stress, or heat shock, cytoplasmically mislocalized FUS 
variants incorporated into stress granules (Bosco et al., 2010a; Dormann et al., 
2010; Gal et al., 2011; Kino et al., 2011). This led to a two-hit hypothesis wherein 
the genetic mutations that result in cytoplasmic mislocalization of FUS represent 
the first-hit while the stress conditions represent the second-hit (Dormann and 
Haass, 2011).  The work presented in chapter II demonstrating the pro-survival 
role of FUS under hyperosmolar stress conditions provides a basis for examining 
not only the role of hyperosmolar stress as that second-hit stressor but also the 
role of osmotic imbalance in ALS and neurodegeneration in general. 
ALS and Hyperosmolar Stress 
Interestingly, several studies and observations point towards a role of 
hyperosmolar stress in ALS. First, other ALS proteins are implicated in 
hyperosmolar stress response.  Similar to FUS, the ALS-associated proteins 
TDP43 and hnRNP A1 respond to hyperosmolar stress by translocating into the 
cytoplasm and incorporating into stress granules (van der Houven van Oordt et 
al., 2000; Guil et al., 2006; Dewey et al., 2010; Sama et al., 2013). Indeed, these 
proteins are required for recovery and/or survival of cells under hyperosmolar 
stress conditions. Expression of mutant-tdp-1, an orthologue of TDP43, in C 
elegans increased the sensitivity of the worms to osmotic stress (Vaccaro et al., 
2012). Similarly, the neurodegenerative phenotype observed in mutants of alpha-
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1, an orthologue of ALS causing gene C9ORF72, was worsened by osmotic 
stress in C elegans (Therrien et al., 2013). SOD1, another ALS associated 
protein, is required for survival of S. cerevisiae under hyperosmolar stress 
conditions (Garay-Arroyo et al., 2003). Furthermore, since cytoskeletal 
rearrangement is a pronounced feature during hyperosmolar conditions (Brocker 
et al., 2012), it wouldn’t be surprising if the recently discovered ALS protein 
Profilin 1, a key regulator of actin dynamics (Wu et al., 2012), also responds and 
has a role under such stress conditions.  
Second, several key cellular adaptive and pathogenic events in response 
to hyperosmolar stress overlap with the pathogenic events reported in ALS. Cell 
shrinkage caused by hyperosmolar stress triggers many adverse subcellular 
events, such as oxidative stress, mitochondrial depolarization, inhibition of DNA 
replication and transcription, damage to DNA and proteins, and cell cycle arrest, 
all of which can ultimately lead to apoptosis (Alfieri and Petronini, 2007; Burg et 
al., 2007; Brocker et al., 2012).  Interestingly, protein misfolding and aggregation, 
oxidative stress, mitochondrial dysfunction, and impaired DNA/RNA metabolism 
have all been suggested to contribute to ALS pathogenesis and ultimately lead to 
apoptosis of motor neurons (Pasinelli and Brown, 2006). Furthermore, 
inflammation, a key contributor to ALS pathogenesis (Barbeito et al., 2010; Calvo 
et al., 2010; Papadimitriou et al., 2010), is tightly linked with hyperosmolar stress 
(Brocker et al., 2012). Despite being controversial, strenuous exercise, sports 
and intense physical activity have been linked to ALS (Scarmeas et al., 2002; 
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Chio et al., 2005; Beghi et al., 2010; Huisman et al., 2013). It is possible that the 
dehydration/osmotic imbalance resulting from these intense activities is causal 
for ALS through a hyperosmolar stress response. Moreover, hyperosmolar stress 
is implicated in a myriad of disease conditions in humans, including renal failure, 
diabetes, inflammation as well as disorders of the eye, heart and liver (Brocker et 
al., 2012) underscoring its importance in disease. Despite these studies and 
observations, further research must be done to conclusively determine the role of 
hyperosmolar stress in ALS. 
Osmotic stress – sensing mechanisms 
In order to understand the potential role of FUS in response to 
hyperosmolar stress, several mechanisms involved in sensing the stress and 
signaling are discussed below (summarized in Fig 4.1). The mechanisms by 
which mammalian cells detect changes in extracellular osmotic concentrations, 
however, are poorly understood. Exposure of cells to hypotonic or hypertonic 
medium induces rapid cellular swelling or shrinkage, respectively, and thus cell 
volume appears to be the key parameter that is monitored to induce a cellular 
response. Changes in cell volume trigger adaptive responses to either mitigate 
the toxic effects or initiate apoptosis. Interestingly, numerous other processes 
and pathways including metabolism, cell division, migration, motility, membrane 
trafficking and apoptosis are regulated by cell volume changes (Lang et al., 
1998). But exactly how is the volume of a cell registered/monitored under 
osmotic stress conditions? While there are no clear answers, recent studies point 
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toward characteristics such as macromolecular crowding, plasma membrane 
properties, cytoskeletal organization, ionic strength and structural changes of 
intracellular organelles as potential indicators of cell volume changes (Schliess et 
al., 2007).  Each is discussed below.  
Macromolecular crowding:  Increased macromolecular crowding can alter 
molecular interactions as well as the stability and structure of DNA, RNA and 
proteins. Such changes can have a profound effect on key cellular processes 
such transcription and translation (Morelli et al., 2011). In fact, changes in 
cytoplasmic protein concentration have been shown to act as an indicator of cell 
volume changes (Colclasure and Parker, 1992; Parker and Colclasure, 1992; 
Garner and Burg, 1994). Thus macromolecular crowding can contribute to the 
osmosenisng mechanism of the cell. 
Plasma membrane properties:  Plasma membrane properties such as tension, 
composition and membrane curvature are potential indicators of cell volume 
alterations (Schliess et al., 2007). Stretch-activated ion channels, which are 
mechanosensitive channels localized to plasma membranes, play a role in both 
hypo- and hyperosmolar stress conditions. For instance, the TRP (Transient 
Receptor Potential) family channels respond to changes in osmotic conditions 
and are well studied in the context of cell volume regulation (Pedersen and 
Nilius, 2007). Additionally, cell adhesion molecules such as integrins and 
cadherins, which are involved in binding with other cells or the extra cellular 
matrix, are also potential cell volume sensors (Haussinger and Lang, 1992; Ko et 
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al., 2001; Juliano, 2002; Moeckel et al., 2006). Finally, although there is no 
evidence that they respond to osmotic stress, BAR (Bin–Amphiphysin–Rvs) 
domain containing family of proteins are implicated as candidates with the 
potential to sense osmotic stress (Zulys, 2008). These proteins, which are curved 
(banana-shaped) themselves, bind to curved membranes and have different 
curvature preferences (Peter et al., 2004; Zimmerberg and McLaughlin, 2004; 
Gallop and McMahon, 2005). Furthermore, BAR domain family proteins are 
implicated in numerous cellular functions that could be relevant to osmotic stress, 
such as actin cytoskeletal regulation, secretory vesicle fusion, ion flux across 
membranes, signal transduction and apoptosis (Ren et al., 2006). 
Cytoskeletal organization:  Although the role of the cytoskeleton as an 
osmosensor is controversial, cytoskeletal rearrangement is known to occur 
during cellular swelling or shrinkage and therefore cytoskeletal dynamics may 
contribute to the osmosensing mechanisms of the cell. Furthermore, the 
structural reorganization of actin filaments could regulate membrane channels 
that impact cell volume homeostasis (Henson, 1999; Pedersen et al., 2001).   
Ionic strength:  The concentration of intracellular ions may also contribute to the 
cellular sensing of osmotic imbalance (Gamba, 2005). Altered ionic strength can 
stimulate ion transporters (Nilius et al., 1998) and activate signaling cascades 
involved in cell volume regulation (discussed further below)  (Di Ciano-Oliveira et 
al., 2003; Nielsen et al., 2007). 
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Structural changes of intracellular organelles:  Osmotic stress induced defects in 
endoplasmic reticulum (ER) to golgi transport, result in loss of structural integrity 
of those organelles (Lee and Linstedt, 1999). Furthermore, mitochondrial 
fragmentation has been reported as a response to hyperosmolar stress (Zulys, 
2008).  Such a loss of structural integrity of major organelles is associated with 
cellular stress response (Welch and Suhan, 1985; Hicks and Machamer, 2005) 
and thus could be a potential indicator of cell volume changes. 
Thus, it appears that the cells employ several sensing mechanisms, which alone 
or in combination, may trigger adaptive responses.  
Hyperosmolar stress – signaling and effects 
Despite specific signaling events and effects associated with hypoosmolar stress, 
due to the response of FUS to hyperosmolar stress, the discussion below is 
focused on the signaling events and their effects in response to hyperosmolar 
stress.  Hyperosmolar stress triggers several pathways including receptor and 
non-receptor tyrosine kinases, MAP kinases, lipid kinases, serine/threonine 
kinases and the Rho family small GTPases (Fig 4.1). The specific roles of each 
of these pathways have been discussed in detail elsewhere (Zulys, 2008). Of 
interest to my current research is the p38 MAP kinase, which mediates the 
pathogenic effects of mutant FUS proteins in the squid axoplasm (Chapter 3).  
The upstream events of p38 MAPK activation include the binding of OSM 
(Osmosensing Scaffold for MEKK3) to the GTPase Rac and the kinases MEKK3 
(MAPK/extracellular-regulated kinase (ERK) kinase kinases) and MKK3 
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(Mitogen-activated protein kinase kinase kinase 3) (Uhlik et al., 2003). The 
activated p38 translocates to nucleus and enhances the transcriptional activity of 
NFAT5 (Nuclear factor of activated T-cells 5), also known as TonEBP/OREBP, a 
transcription factor that, among other things, drives the expression of genes 
involved in osmolyte synthesis and channel proteins (Ko et al., 2002). The 
transcriptional activity of NFAT5 is regulated by the presence of a DNA sequence 
element known as the osmotic response element (ORE) or tonicity enhancer 
(TonE) sequence upstream of the various osmoprotective genes (Ferraris et al., 
1996; Ko et al., 1997; Miyakawa et al., 1998; Ko et al., 2000). Hyperosmolar 
stress induces translocation of NFAT5 from cytoplasm to nucleus (Cai et al., 
2005), where it binds the ORE as a homodimer (Stroud et al., 2002). The 
translocation of NFAT5 appears to be regulated by phosphorylation of its serine 
and tyrosine residues and/or its dimerization ability (Dahl et al., 2001). The best 
studied genes regulated by NFAT5 include transporters, which restore ionic 
homeostasis by transporting organic osmolytes such as glycine, betaine, 
ionositol and taurine into the cell, as well as enzymes such as aldose reducatse 
involved in sorbitol synthesis (Smardo et al., 1992). NFAT5 also regulates the 
transcription of the molecular chaperone HSP70 (Woo et al., 2002), which aids in 
restoring protein folding, and aquaporins (Hasler et al., 2006), which regulate 
water permeability of membranes. Although NFAT5 is the most studied regulator 
of gene expression in response to hyperosmolar stress, changes in levels of 
several proteins that are not known to be regulated by NFAT5 have been 
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reported (Mao et al., 2008; Soufi et al., 2009), suggesting the influence of other 
transcription factors and/or signaling processes in regulating gene expression. In 
fact, regulation of mRNA turnover in yeast cells contributes to altered gene 
expression (Romero-Santacreu et al., 2009). Furthermore, several studies 
provide evidence for translational inhibition in response to hyperosmolar stress 
supporting that gene expression under such conditions is regulated at multiple 
levels (Burg et al., 2007). 
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Figure 4.1 
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Figure 4.1 Potential sensing mechanisms, signaling and gene expression 
regulation in response to hyperosmolar stress 
Hyperosmolar stress induced cell shrinkage is detected by a single or 
combination of parameters including membrane properties, macromolecular 
crowding, cytoskeleton organization, ionic strength and intracellular organelle 
structures. Upon detection of hyperosmolar stress, several key signaling 
cascades such as receptor- and non-receptor tyrosine kinases, MAP kinases, 
lipid kinases, other serine/threonine kinases and RHO GTPases mediate the 
subsequent gene expression changes (discussed in detail in (Zulys, 2008)).Gene 
expression is regulated at transcriptional level (transcription factors such as 
NFAT5 and splicing regulation) and translational level (mRNA stability/turnover) 
modulating the expression of proteins involved in key cellular functions including 
osmolyte synthesis, ion transport, protein folding, inflammation and apoptosis. 
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FUS and Hyperosmolar stress 
Hyperosmolar stress induces cytoplasmic translocation of FUS, which plays a 
pro-survival role under such conditions (Sama et al., 2013). What is the 
mechanism by which FUS plays this role? FUS is an RNA binding protein and 
binds to transcripts of several hundred genes involved in key cellular functions 
(Table 1.1). Knock-down of FUS alters the binding of FUS to those transcripts 
and also results in altered expression and splicing of transcripts (Table 1.1). 
Albeit in a study using ALS causing mutant FUS, cytoplasmic mislocalization of 
FUS has been implicated in altered expression and splicing of several hundred 
mRNAs (van Blitterswijk et al., 2013). These studies suggest that factors 
affecting the expression and or localization of FUS could have profound effects 
on gene expression. Hyperosmolar stress-induced cytoplasmic accumulation of 
FUS is also accompanied by a nuclear depletion of FUS, possibly effecting the 
expression of several genes.  Of interest would be to determine if those genes 
are involved in apoptosis, since reduced FUS levels rendered cells susceptible to 
hyperosmolar stress induced toxicity (Sama et al., 2013). Furthermore, the 
translation and expression of pro-survival proteins XIAP (X-linked inhibitor of 
apoptosis protein) and Bcl-xL (B-cell lymphoma-extra large) (Lewis et al., 2007; 
Bevilacqua et al., 2010) during hyperosmolar stress is regulated by hnRNP A1, 
another RNA binding protein that also translocates to the cytoplasm and 
incorporates into stress granules in response to hyperosmolar stress (van der 
Houven van Oordt et al., 2000). It is possible that FUS exerts a similar effect on 
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specific genes involved in apoptosis by regulating their expression and/or 
splicing. It is also possible that FUS might exert such an effect indirectly by 
modulating the functions of other proteins. For instance, FUS is known to interact 
with both hnRNP A1 (Perrotti et al., 2000; Iervolino et al., 2002) and TDP-43 (Kim 
et al., 2010), proteins that also translocate to the cytoplasm and incorporate into 
stress granules in response to hyperosmolar stress (van der Houven van Oordt 
et al., 2000; Dewey et al., 2010). Nevertheless, given that not all RNA binding 
proteins respond to hyperosmolar stress (van der Houven van Oordt et al., 2000) 
and that WT FUS responds selectively to hyperosmolar stress (Sama et al., 
2013) is suggestive of a specific functional role for FUS during hyperosmolar 
stress. 
Methylation of FUS and ALS 
Post translational modifications (PTMs) regulate key cellular events and 
are a major factor in the pathogenesis of several diseases (Karve and Cheema, 
2011). In particular, protein arginine methylation regulates several cellular 
processes and has been implicated in many human diseases (Aletta and Hu, 
2008). Interestingly protein arginine methylation, regulated largely by PRMT1 
(protein argnine methyl transferase), has been shown to dictate the subcellular 
distribution of endogenous as well as ALS-linked FUS (Du et al., 2011; Dormann 
et al., 2012; Tradewell et al., 2012; Yamaguchi and Kitajo, 2012). Furthermore, 
inclusions in ALS-FUS patients contained methylated FUS while inclusions in 
FTD-FUS were devoid of methylated FUS, indicating a role for protein arginine 
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methylation in disease pathogenesis (Dormann et al., 2012). In chapter II we 
show that the subcellular distribution of FUS in response to hyperosmolar stress 
is also regulated by methylation (Fig 2.8). Further investigation is needed to 
determine if PRMT1 specifically regulates FUS localization under hyperosmolar 
stress conditions as well. Our data shows, however, that methylation did not 
have any role in regulating the incorporation of FUS into stress granules (Fig 
2.9), indicating that the arginine methylation status affects only certain aspects of 
FUS. 
A model for FUS in cellular stress response and ALS 
What is the role of FUS in cellular stress response and what are the 
implications of its role in ALS? While much more research has to be done to 
precisely answer these questions, the current knowledge from our work here and 
published work from others lead to a model as described below. Under normal 
conditions WT FUS is predominantly localized to the nucleus. However, FUS is 
involved in RNA transport and shuttles between the nucleus and cytoplasm and 
hence a minor fraction of FUS is present in the cytoplasm (Fig 4.2A). On the 
other hand, a majority of ALS-linked FUS variants undergo varying degrees of 
mislocalization to the cytoplasm causing a corresponding nuclear depletion of 
FUS (Fig 4.2A). Under stress conditions such as oxidative stress, heat shock and 
ER stress, the WT FUS remains nuclear and only the small fraction in the 
cytoplasm incorporates into stress granules (Fig 4.2B), perhaps making it difficult 
to detect by routine immunofluorescence techniques. However, under those 
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stress conditions, ALS-variants that are already in the cytoplasm due to 
mutations incorporate into stress granules (Fig 4.2B). Such an incorporation of 
FUS variants into stress granules suggest a gain-of-toxic function by the FUS 
variants. However, a similar gain-of-toxic function mechanism cannot be applied 
to mutations that do not induce cytoplasmic mislocalization, such as those in the 
Gly-rich region, as these proteins remain nuclear with or without the 
aforementioned stress conditions. Hyperosmolar stress on the other hand causes 
endogenous WT FUS to undergo cytoplasmic translocation and incorporation 
into stress granules (Fig 4.2C). The question that remains is how do FUS 
variants respond to hyperosmolar stress? Assuming a loss of nuclear function by 
ALS-causing FUS variants, hyperosmolar stress could worsen this condition as 
the nucleus is further deprived of functional FUS protein under such conditions 
(Fig 4.2C). Assuming a cytoplasmic gain-of-toxic function mechanism by FUS 
variants, once again this condition could be worsened by hyperosmolar stress as 
more protein accumulates in the cytoplasm as a result of translocation of WT 
FUS (Fig 4.2C). Thus hyperosmolar stress is a suitable model of disease for not 
only the cytoplasmically mislocalized FUS, but also for the variants that retain 
nuclear localization. However, further investigation is needed to determine the 
relevance of hyperosmolar stress in ALS.  
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Figure 4.2 
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Figure 4.2 The different responses of FUS variants to cellular stress.  
Cells expressing exogenous WT- or endogenous FUS (top panels) and ALS-
linked FUS varaints (bottom panels) are shown under different cellular 
conditions. A) Under normal conditions WT/endogenous FUS is localized 
predominantly to the nucleus while ALS-linked FUS variants (i.e., with mutations 
in the nuclear localization domain) undergo varying degrees of cytoplasmic 
mislocalization. B) Under conditions of oxidative stress, heat shock or ER stress, 
WT/endogenous FUS remains nuclear while FUS variants that are already 
mislocalized to cytoplasm incorporate into stress granules. C) Under conditions 
of hyperosmolar stress, WT/endogenous FUS translocates to cytoplasm and 
incorporates into stress granules.  Under these conditions, endogenous FUS is 
thought to play a pro-survival role. FUS variants that are already mislocalized to 
cytoplasm also associate with stress granules (unpublished data), although the 
implications of this interaction for ALS are unknown.   
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Misfolding of FUS – Insights and Implications 
Cytoplasmic mislocalization has been largely attributed to the pathogenic 
effects of FUS variants. For instance, ALS-causing mutations in FUS do not 
disrupt its ability to bind RNA.  However, a subset of mRNAs are bound by 
cytoplasmic mutant-FUS and not by WT FUS, which has been attributed to the 
mislocalization of mutant-FUS (Hoell et al., 2011). Furthermore, as mentioned 
earlier, the role of FUS in stress granules under certain stress conditions is only 
applicable to variants that are already mislocalized to the cytoplasm. Cytoplasmic 
mislocalization however, is not the only feature of FUS variants that contributes 
to ALS pathogenesis. In chapter III of this dissertation we show that ALS-linked 
FUS variants inhibit axonal transport, whereas WT do not, despite being located 
outside of the nucleus.  In this case, localization of the protein was not a factor, 
and instead, the inhibition of axonal transport was attributed to the misfolding of 
the mutant-FUS. Protein misfolding has indeed been suggested as part of ALS 
pathogenesis owing to an impairment of protein homeostasis during aging as 
well as the increased aggregation propensity of mutant proteins, as in the case 
for SOD1 (Pasinelli and Brown, 2006). However, even though WT FUS was 
shown to be extremely aggregation prone by itself, ALS mutations did not 
enhance its aggregation propensity (Sun et al., 2011). How then do FUS 
mutations exert their pathogenic effects? In order to address this question we 
made use of N-terminally GST-tagged recombinant WT and ALS-linked FUS 
variants expressed in E. coli. In contrast to other types of recombinant FUS 
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proteins, including untagged FUS or  N- and C-terminally His-tagged FUS, N-
terminal GST tagged FUS remains soluble (Sun et al., 2011). Furthermore, 
despite the GST-tag, the recombinant FUS proteins retain several key functions 
and appear to be very similar to cellular FUS (Kim et al., 2010; Wang et al., 2013; 
Qiu et al., 2014). 
A limited proteolysis experiment showed that the ALS-linked FUS variants 
are structurally different from WT FUS (Fig 3.3). Mass spectrometry analysis of 
differentially cleaved peptides identified a region in the N-terminal prion like 
domain of mutant-FUS that is protected despite being digested in the WT FUS. 
Interestingly, the N-terminal prion like domain is essential for the aggregation of 
FUS (Sun et al., 2011). This could imply that the FUS variants used in our 
analysis were aggregated and thus the N-terminal region was protected from 
proteolytic digestion. Thus, it would be very informative to determine if there is 
any aggregation/oligomerization of the FUS proteins. Despite that, tryptophan 
fluorescence anisotropy also clearly showed that the FUS variants are 
structurally different than that of WT in solution.  These insights into the structural 
differences between WT and FUS variants raise a few important questions. Why 
is this N-terminal aggregation-prone region protected in FUS variants, but 
exposed in the WT protein? Furthermore, how do mutations in the C-terminal 
region (R521G and R495X) and Gly-rich region (G230C) result in structural 
differences at the N-terminus of the protein? One possibility is that the mutations 
in various regions of FUS can induce allosteric perturbations in the protein that 
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somehow propagate to the N-terminal region. Further structural analysis of FUS 
will provide a much needed insight into the pathogenic effects of its variants. 
Why is untagged FUS extremely aggregation prone and insoluble? FUS is 
a DNA/RNA binding protein and most of the functions of FUS have to do with its 
ability to bind DNA and/or RNA. Furthermore, FUS is found in complexes with 
several other cellular proteins and some of those interactions are even mediated 
by RNA. Thus the environment of the cell provides factors that can stabilize FUS, 
which is difficult to replicate in in vitro experiments. This also underscores that 
such an environment can have a profound effect on the structure of the FUS. 
While it is difficult to exactly replicate such conditions, we are currently 
investigating the binding effect of known sequences of DNA and RNA, which 
have high affinity for FUS, on the structure of the protein. In particular the effect 
of DNA/RNA binding on limited proteolysis with chymotrypsin is being examined. 
Furthermore, assays that can at least partially replicate the cellular environment 
would be of even more relevance in understanding the pathogenic nature of FUS 
variants. We have therefore employed the squid axoplasm based vesicle motility 
assays to study the effect of FUS proteins on axonal transport. 
Axonal transport and ALS 
Axons are a unique feature of neurons, with some types of neurons having 
axons up to thousand times larger than their cell bodies. With only limited protein 
synthesis occurring in the axonal compartment, cells rely heavily on axonal 
transport to traffic proteins and cargo between the cell body and synapse. Thus 
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impaired axonal transport has been implicated in numerous diseases related to 
neurons (Morfini et al., 2009). Both upper and lower motor neurons are 
selectively vulnerable in ALS.  Despite an in depth investigation of the 
mechanisms of ALS-associated genes, little is known about the reason behind 
selective vulnerability of the motor neurons. Defects in axonal transport have 
been documented early on in ALS patients (Sasaki and Iwata, 1996) and similar 
defects have also been found in animal models of ALS (Sasaki et al., 2005) 
providing a basis for selectivity of motor neuron degeneration in ALS. Thus we 
have examined the effect of the FUS proteins on axonal transport in squid 
axoplasm and demonstrated that the FUS variants specifically inhibited axonal 
transport in both anterograde and retrograde directions (Fig 3.7). These results 
further highlight the role of impaired axonal transport as a pathogenic event in 
ALS. Interestingly, transgenic rats expressing mutant-FUS display degeneration 
of the motor axons, however, the role of axonal transport in such degeneration 
has not been investigated (Huang et al., 2011). Further investigation into aspects 
of axonal transport with assistance from reliable ALS-FUS animal models could 
address whether transport defects occur early on and are part of the disease 
pathogenesis or not.  
The recent discovery of ALS causing mutations in genes such as FUS, 
TDP43, PFN1 and C9ORF72, implicate several pathways in the disease 
pathogenesis. However, a majority of these pathways have been specific to only 
a subset of these proteins and cannot explain a common pathogenic property of 
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ALS proteins. In chapter III, we show that ALS-linked FUS variants inhibit fast 
axonal transport (FAT) in a squid-based vesicle motility assay (Fig 3.7). 
Interestingly ALS-causing mutant-SOD1, as well as misfolded WT SOD1 
implicated in sporadic ALS, also inhibits FAT in similar assays (Bosco et al., 
2010b; Morfini et al., 2013).  Furthermore, for both proteins, the inhibition is 
mediated by p38 MAPK. In the case of FUS, the inhibition is potentially mediated 
by either the p38β isoform alone or both p38 α and β isoforms, as inhibition is 
observed in both anterograde and retrograde directions (Fig 3.8 and (Morfini et 
al., 2013)). In the case of SOD1 mediated inhibition on the other hand, the 
inhibition is potentially mediated by p38α isoform, as this isoform specifically 
inhibits the anterograde FAT. Despite these differences, in both cases the 
upstream kinase ASK1 is involved demonstrating the involvement of the kinase 
cascade (Fig 3.9). In fact, the p38 MAP kinase cascade has been implicated in 
several neurodegenerative diseases (Correa and Eales, 2012). Phosphorylated 
p38 MAPK, representing the active form of the protein, regulates key signaling 
events and is often indicative of the involvement of the kinase cascade in several 
cellular events.   Increased immunoreactivity for activated p38 MAPK has been 
reported in spinal cord tissue of ALS patients (Bendotti et al., 2004). 
Furthermore, activated p38 has been detected in spinal cord motor neurons of 
early and late stage SOD1-ALS transgenic mice (Tortarolo et al., 2003; Morfini et 
al., 2013). Thus we investigated the activation of p38 MAPK as well as its 
expression in ALS-FUS patients and demonstrated that several patients had 
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higher p38 levels and activation (Fig 3.10).  That some ALS-FUS tissue samples 
lacked a large p38 signal could be explained by differences in tissue collection 
and storage conditions, which could affect protein integrity. Furthermore, due to 
the limited availability of the tissue, the samples were not matched for age, 
gender or any demographic attributes raising the need for caution in interpreting 
these results. Nevertheless, investigating if other ALS associated proteins have 
similar effects on axonal transport and if such an effect is mediated by p38 MAPK 
would unravel its role in ALS. 
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CONCLUSION 
ALS is a fatal neurodegenerative disease and there is still no cure to this 
disease. Research has advanced greatly over years and several new genes that 
cause ALS have now been identified. Investigation of these genes provided great 
insights into the disease causing mechanisms. The current dissertation aimed at 
investigating one such gene, FUS/TLS or FUS, and identified a novel functional 
role for the protein under hyperosmolar stress. The work presented also lays 
precedence for investigating the role of hyperosmolar stress in ALS. 
Furthermore, the investigation of the role of FUS variants in ALS identified that 
protein misfolding and aberrant kinase activation contribute to pathogenic effects 
of the FUS mutations. The findings of this dissertation will not only extend our 
current understanding of the disease but also could provide directions to develop 
treatment and/or cure for ALS.  
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APPENDIX I 
A large part of this work was done by Syed Noorwez (SN) with the following 
exceptions: Western blots analyses and immunoprecipitation were performed by 
Reddy Ranjith K Sama (RRKS) and SN. Plasmid transfections were performed 
by RRKS.  
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APPENDIX II 
Desiree Baron (DB), Laura Kaushansky (LK), and Catherine Ward planned and 
performed the majority of experiments; DB, Alex J. Quaresma and Jeffrey A. 
Nickerson planned, performed and analyzed data for FRAP; Ru-Ju Chian cloned 
deletion constructs for structure-function analyses; Reddy Ranjith K Sama and 
Kristin Boggio contributed to the design and data interpretation for experiments. 
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